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Abstract: The most recent opioid epidemic in United States history emerged in the late 1980s and 
continues its destructive impact to this day. It has evolved into a devastating public health crisis 
with a broad range of medical, social, and economic consequences. This dissertation focuses on 
the “first wave” of this opioid epidemic characterized largely by the misuse of prescription 
opioids. The research questions here were focused on developing a greater understanding of the 
social processes involved in young women’s initiation of prescription opioid misuse (POM) 
during this first wave. The research methodology consisted of a cross-sectional, exploratory 
study using qualitative data collection and analytic methods in the grounded theory tradition. An 
ecosystems perspective was used in the categorization of findings at the individual, interpersonal, 
and community levels, and a description of the POM initiation trajectory experienced by 
participants is described. A grounded theory that emerged from these findings is presented, as are 
key themes that include the importance of an initiation trajectory as a concept replacing the 
term initiation; the impact of female gender on this particular initiation trajectory; the lack of 
evidence-based information about addiction across the prevention, treatment, and recovery 
landscape; key differences between POM and other substance misuse trajectories; the 
contribution of stigma as a barrier to accessing support for substance misuse; and an examination 
of the connections between boredom, lack of meaning and substance misuse outcomes. Study 
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findings point to a set of recommendations for interventions at the individual, interpersonal, and 
community levels that can inform practice, policy, and research moving forward. 
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CHAPTER I: INTRODUCTION AND STATEMENT OF THE PROBLEM 
 For centuries, humans have used opium and its derivatives as powerful healing 
substances. These have proven to be highly effective treatments for pain, digestive problems, 
insomnia and psychological distress (Courtwright, 2001; Davenport-Hines, 2004; Inaba & 
Cohen, 2011). But along with opium’s powerful healing properties come equally significant 
consequences, including substance misuse, health complications and death. While many are able 
to use opioids with no adverse consequences, others develop a relationship to these substances 
that is damaging to themselves, their families, and their communities. Humans continue to 
struggle with this very complex relationship to the poppy plant—attempting to benefit from its 
gifts while not falling victim to its destructive potential. 
The most recent manifestation of this age-old struggle emerged in the United States in the 
late 1980s and has evolved into the current opioid epidemic. Dr. Nora Volkow, the Director of 
the National Institute on Drug Abuse (NIDA) states that this epidemic is “one of the most severe 
public health crises in US history” (Volkow & Blanco, 2020). This dissertation focuses on the 
first wave of the epidemic characterized by the misuse of prescription opioids1. Subsequent 
waves of the opioid epidemic have been driven by increases in use of heroin (second wave), and 
synthetic opioids (third wave) (Volkow & Blanco, 2020).2  
                                                 
1 A prescription opioid is distinguished from others in the opioid family in that (1) it is intended 
for use under a medical professional’s supervision and (2) it originates as a legally manufactured 
and distributed substance. For the purposes of this study, prescription opioid misuse (POM) is 
defined as “use in any way not directed by a doctor, including use without a prescription of one’s 
own; use in greater amounts, more often, or longer than told to take a drug; or use in any other 
way not directed by a doctor” (Substance Abuse and Mental Health Services Administration, 
2016).  
2 Prescription opioids (also known as painkillers, opioid pain relievers or opioid analgesics) are 
part of the larger opioid family of substances. The term opioid refers to the entire group of 
narcotic analgesics comprised of (a) opiates, (b) semisynthetic opiates, and (c) fully synthetic 
opioids. Opiates are natural derivatives of opium from the poppy plant and include substances 
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In the late 1980s, a confluence of circumstances coalesced to drive a dramatic increase in 
prescription opioid misuse (POM) and resulted in the first wave of the current opioid epidemic. 
Rates of POM escalated rapidly through the 1990s, reaching its height in 2006 (Compton et al., 
2016). Although there has been an overall downward trend since 2012, POM is still widespread. 
Prescription opioids continue to be the second most commonly used illicit substance in this 
country after marijuana, according to the National Survey on Drug Use and Health (NSDUH) 
(Substance Abuse and Mental Health Services Administration, 2019b). In 2018, 9.9 million 
people aged 12 or older misused a prescription opioid in the past year--about 3.6% of the 
population (Substance Abuse and Mental Health Services Administration, 2019b).  
The widespread misuse of prescription opioids has been accompanied by serious public 
health consequences. The proportion of admissions to substance use treatment facilities that 
involved opioids other than heroin as the primary substance of abuse at admission increased from 
3% of all admissions aged 12 and older in 2004 to 10% in 2012 (Center for Behavioral Health 
Statistics and Quality, 2016). Trends related to fatal overdoses are also extremely concerning. 
Between 1999 and 2017, 702,568 people died of a drug overdose in this country (Scholl, 2019). 
Almost a third of these overdose deaths (31%) involved a prescription opioid (Centers for 
Disease Control, 2019). 
                                                 
such as morphine and codeine. Semisynthetic opioids are chemically modified opiates, such as 
hydrocodone (e.g., Vicodin), hydromorphone (Dilaudid), oxycodone (e.g. OxyContin, Percocet), 
oxymorphone and heroin. Fully synthetic opioids are manufactured entirely from synthetic 
materials. Examples of these include fentanyl, methadone, and tramadol (Booth, 1999, p. 82). 
The prescription opioids considered in this study are found in all three groups (opiate, 
semisynthetic opiate and fully synthetic opioid). Prescription opioids are also referred to in this 




The second wave of the opioid epidemic followed on the heels of the first. Heroin misuse 
began to increase steadily around 2006 and has been rising ever since (Compton et al., 2016). 
Although heroin misuse is still much less prevalent than POM, rising rates are nevertheless 
concerning. NSDUH data show that 914,000 people misused heroin in 2014, a 145% increase in 
ten years (Compton et al., 2016). Mortality related to heroin misuse has also increased 
dramatically, climbing from 1,842 deaths in 2000 to 10,574 deaths in 2014 (Compton et al., 
2016).  
There are consistent findings that indicate positive associations between nonmedical 
prescription opioid and heroin misuse (Davis & Johnson, 2008; Grau et al., 2007; Muhuri et al., 
2013). Community-based studies have demonstrated that significant numbers of current heroin 
users report misuse of prescription opioids prior to initiating heroin (Lankenau et al., 2012; 
Peavy et al., 2012; Pollini et al., 2011). National data shows that this number has increased 
substantially. In 2002-2004, 64% of heroin users reported the misuse of painkillers prior to 
heroin initiation; by 2008-2010, this amount had climbed to 83% of heroin users (Jones, 2013). It 
is clear that prescription opioid misuse precedes heroin misuse in increasing numbers of 
individuals. 
One explanation for this increase in heroin misuse points to supply-side policy 
interventions which curbed opioid prescribing: prescription monitoring programs, physician 
education and abuse deterrent opioid formulations (Cicero et al., 2017). Despite some success in 
the reduction of diverted painkillers (Dart et al., 2015), a secondary consequence of these policy 
measures was to push some who were misusing painkillers into the heroin market due to the fact 
that heroin was less expensive, readily available and generally more potent (Cicero et al., 2014; 
Compton et al., 2016).  
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While misuse of prescription opioids can have devastating consequences, the transition to 
heroin carries an additional layer of risk. For some, method of use changes with the transition to 
heroin. Many individuals shift from oral or intranasal use to intravenous (IV) use:69.7% of 
heroin users are IV users, compared with 14.3% of those who misuse prescription opioid 
misusers (Substance Abuse and Mental Health Services Administration, 2012b). Intravenous use 
is also associated with an increased risk of HIV and Hepatitis C, scarred or collapsed veins, 
bacterial infections of the blood vessels and heart valves, abscesses, and other soft-tissue 
infections (National Institute on Drug Abuse, 1997). The use of an unregulated substance such as 
heroin also involves increased risk of injecting a contaminant which can lead to infection and 
death of cells in the lungs, liver, kidneys, or brain (National Institute on Drug Abuse, 1997). 
The opioid epidemic’s third wave involved increasing numbers of people misusing 
fentanyl and other synthetic opioids. Substances in the fentanyl family are powerful opioids that 
can be 30-50 times more potent than heroin). As a result, heroin is increasingly likely to be 
adulterated with fentanyl or a fentanyl analogue (Ciccarone et al., 2017). Between 2010 and 
2017, deaths from fentanyl increased from 14% to 59.8% of all opioid-related deaths 
(Hedegaard, 2018). It is unclear how many users actively seek out fentanyl specifically, or are 
being exposed unwittingly. Regardless, exposure to fentanyl greatly increases the risk of opioid 
overdose. 
The opioid epidemic has had enormous medical, social and economic consequences. In 
pure dollars, the epidemic has cost the US at least $631 billion (Society of Actuaries, 2019). Key 
findings from this study of the economic impact of the epidemic showed this amount was due to 
excess healthcare spending, premature mortality, criminal justice activities, child and family 





Although individuals of all ages misuse prescription opioids, this study focuses on young 
adults between the ages of 18 and 34. This age group roughly corresponds to the Millenial 
Generation, those born between 1982 and 2005 (Howe & Strauss, 2000). In 2018, about 1.9 
million young adults aged 18-25 misused a prescription opioid, about 5.5% of young adults in 
this age group (Substance Abuse and Mental Health Services Administration, 2019b). This 
number has dropped in recent years from almost 9% in 2015. Nevertheless, it still remains higher 
than all other age groups. Although nonmedical prescription opioid misuse has increased across 
all cohorts, rates continue to be highest among Millennials (Miech et al., 2013). 
Gender 
Studying the distinct dynamics of substance use in women is vitally important (Tuchman, 
2010). Historically, participants in substance use research have been men, similar to other public 
health research. New studies have shown, however, that women’s pathways to substance use 
disorders are frequently gender-specific or gender-sensitive. While men generally have higher 
rates of use, abuse and dependence for most substances when compared with women (Compton 
et al., 2007; Kessler et al., 2005), the data for prescription opioid misuse are mixed. Some have 
found that women are more likely than men to use painkillers nonmedically (J. P. Kelly et al., 
2008; Simoni-Wastila, 2000; Simoni-Wastila et al., 2004). Others have found equivalent or 
higher rates for men (Becker et al., 2008; Carise et al., 2007; Tetrault et al., 2008). In 2018, 
NSDUH data found that 4.8 million women reported misusing a prescription opioid in the 




Some of these discrepancies in prevalence might be due to gender differences between 
age cohorts. For example, adolescent females have been found to engage in prescription opioid 
misuse at higher rates than adolescent males (1.4% vs. 8%), but these rates equalize between 
genders for adults age 26 and older (Colliver et al., 2006). These particular results point to a 
possible heightened time period of vulnerability of misuse for girls and women in adolescence 
and young adulthood. These studies demonstrate the importance of examining how gender and 
age interact in this particular substance use pattern, as there is still much to learn in this area. 
The Treatment Episode Data Set (TEDS) collects data from substance use treatment 
facilities across the United States. TEDS data show that upon admission to a treatment facility 
for a substance use disorder, women are almost twice as likely than men to report a prescription 
opioid as their primary substance of abuse (13.8% for women vs. 7.8% for men) (Substance 
Abuse and Mental Health Services Administration, 2014c). Whether this reflects higher rates of 
use, or simply higher rates of treatment-seeking among women is not clear. When looking at 
those in treatment, Back et al. (2011) found that women are more likely to present with 
psychiatric comorbidity, medical problems, employment difficulties, and family and social 
difficulties, as compared with men. Women in the Back et al. study also presented with more 
nonmedical use of other prescription drugs such as barbiturates or sedatives, placing them at 
greater risk for drug interactions and possible overdose (Back, Payne, et al., 2011). 
While men are still more likely to die of an overdose involving a prescription opioid, the 
gap between men and women has narrowed in recent years (Centers for Disease Control, 2012). 
In 1999, 1,287 women died of overdoses involving prescription opioids; by 2015, this number 
had climbed to 8,786, an increase of 582% (National Institute on Drug Abuse, 2017). Overdoses 
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among men during this time period rose  from 2,743 to 13,812, a 403% increase (National 
Institute on Drug Abuse, 2017). 
Overall, there has been scant attention paid to gender-specific or gender-sensitive factors 
involved in women’s initiation to prescription opioid misuse. This remains an understudied area, 
despite the fact that women have high levels of nonmedical prescription opioid use disorders, are 
more likely to report nonmedical prescription opioid use upon admission to substance abuse 
treatment, and have increasing rates of prescription opioid involved overdoses. In addition, most 
research examining gender-specific factors is largely epidemiological in nature, focusing on 
demographic trends and risk factors for opioid use disorders.  
Race, Class, and Ethnicity 
Historically, higher rates of prescription opioid misuse and prescription opioid related 
disorders have been seen among Non-Hispanic White individuals than among other racial and 
ethnic groups in the US (Golub & Johnson, 2005; C. R. Green et al., 2005; Mars et al., 2013; 
McCabe, Morales, et al., 2007; Morrison et al., 2000). In recent years, rates for Whites remain 
high, while rates for other ethnic and racial groups have begun to match or even surpass these. 
According to 2013 NSDUH data, 4.2% of the general population (12 or older) acknowledged 
nonmedical prescription opioid use (Substance Abuse and Mental Health Services 
Administration, 2014b). When past year use was broken down by racial and ethnic categories, 
however, higher than average rates were observed for Whites (4.3%), Hispanics (4.5%), 
American Indian/Alaska Natives (6.9%) and those who identify as having two or more races 
(8.1%). Blacks (3.6%) and Asians (1.8%) had lower rates than the national average (Substance 





Initiation of Prescription Opioid Misuse 
Initiation, or first use of a substance, is an important area of attention in substance use 
research. Although many people who initiate the use of a substance will not develop dependence, 
some portion will. The capture rate for any given substance reflects how many people who 
initiate the substance will go on to use it regularly and develop a dependence on it (Anthony et 
al., 1994). Anthony et al. (1994) found lifetime capture rates to be higher for tobacco (31.9%) 
and heroin (23.1%) and lower for cocaine (16.7%), alcohol (15.4%) and cannabis (9.1%). 
Information on prescription opioids was not included in this study, but NSDUH data suggests 
that 40% of individuals who initiated nonmedical prescription opioid misuse reported ongoing 
misuse one year later (Substance Abuse and Mental Health Services Administration, 2008).  
Most studies on substance use initiation have focused on alcohol, marijuana, 
methamphetamine, or MDMA (ecstasy) (Carbone-Lopez et al., 2012; Schmits et al., 2015; 
Trucco et al., 2011; Wu et al., 2010). Researchers have only recently begun to examine the 
dynamics of nonmedical prescription opioid initiation (Daniulaityte et al., 2006; Harocopos & 
Allen, 2015; Rigg, 2012; Rigg & Murphy, 2013). 
In a small qualitative study in New York City (n=19), Haracopos and Allen (2015) 
explored the social and contextual influences of nonmedical prescription opioid initiation among 
adults 18 and older. In this study, 14 men and 5 women were interviewed, ages 20 to 47. 
Researchers found three different typologies of initiation among participants. Recreational 
initiates were introduced to painkillers through drug experimentation during adolescence and 
obtained opioid pills though street sources. Among medical initiates, first use often occurred at 
an older age than in the recreational group and began with medical treatment for an injury or 
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illness that involved a legitimate prescription of an opioid. These users eventually transitioned to 
nonmedical use of prescription opioids. Individuals in the third group, experienced opioid 
initiates, were more diverse in age and were unique in that they were already familiar with 
heroin prior to initiation of prescription opioids. While these findings are helpful in 
understanding pathways to prescription opioid use, the study was limited in that it gave little 
attention to specific factors influencing women’s initiation. 
Geographical Context 
 Staten Island is one of the five boroughs, or counties, that make up New York City. Rates 
of POM have risen in New York City along with the rest of the country, but Staten Island has 
seen some of the highest rates of overdoses of any in the city over the past decade. In 2019, 105 
people in Staten Island died of a drug overdose, a rate of 28.1 per 100,000(NYC Office of the 
Chief Medical Examiner and NYC Health Department’s Bureau of Vital Statistics, n.d.). Other 
boroughs had significantly lower rates—Queens had the lowest overdose rates in the city--12.2 
per 100,000. Brooklyn and Manhattan were also lower—13.9 and 19.9 out of 100,000, 
respectively. Only the Bronx surpassed Staten Island with a rate of 35.2 per 100,000.  
There are several factors that make Staten Island unique among the five boroughs of New 
York City. It is the least populous borough in New York City, with a population of just over 
476,000 (US Census Bureau, 2019). In addition, it is almost 60 miles square, making it the 
borough with the lowest population density (Bauman et al., 2017). Other demographic factors 
also set Staten Island apart. In terms of racial and ethnic distribution, the borough is 60% Non-
Hispanic White, 19% Hispanic, 12% Black, and 11% Asian (US Census Bureau, 2019).This is 
compared with the city overall which is 32% White, 24% Black, 29% Hispanic and 14% Asian 
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(US Census Bureau, 2019)It is the only borough where the majority of residents are non-
Hispanic Whites. 
Staten Island also has the largest percentage of native New Yorkers, that is those that 
were born in New York State—69.46% of Staten Island residents were born in the state as 
compared with the Bronx at 50.35% and 48.76% of Brooklyn residents, Queens at 45% and 
Manhattan at 42% (Crain’s New York Business, n.d.). Within Staten Island, native-born New 
Yorkers are more likely found in the southern part of the island, commonly referred to as the 
South Shore. In the South Shore, 80% of the residents were originally born in the state, the 
highest percent of any neighborhood in the city. Staten Island has the smallest immigrant 
population of any borough, with 23.5% of its residents born outside the US, who mainly live in 
the northern part of the island or the North Shore (NYU Furman Center, n.d.). Staten Island is 
also wealthier and more educated, as compared with the other New York City boroughs. It has 
the highest median household income of any borough--$72,000 as compared with $55,000 city 
wide (Crain’s New York Business, n.d.).  
Statement of Purpose and Research Questions 
The purpose of this grounded theory study was to understand young women’s initiation 
of prescription opioid misuse in Staten Island, New York. Understanding the perspectives of 
these women is critical in order to develop gender-sensitive prevention and treatment efforts that 
address the distinct needs of this population. The central research question focuses on the social 
processes involved in the initiation of these young adult women to nonmedical prescription 
opioid misuse. Specific aims are to explore: (1) how participants describe their initiation 
experiences; (2) in what ways they experience family, peer and intimate relationship contexts as 
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influencing these initiation experiences; and (3) what role, if any, do race, class or ethnicity play 
in the experiences of research participants. 
In Chapter 2, relevant historical, empirical and theoretical literature is reviewed as it 
relates to and informs the current study. Gaps in the literature will be discussed and will 
highlight the significance and value of the research questions. In Chapter 3, the investigator 
discusses research methodology, including epistemological considerations, recruitment 
strategies, instrumentation, data collection, data analysis, and, particularly significant for 
qualitative research, reflexivity and the role of the researcher. Chapters 4 and 5 present study 
findings categorized by individual, interpersonal and community factors. Chapter 6 discusses the 
prescription opioid misuse trajectory from first use to maintenance of addiction. In Chapter 7, the 
grounded theory that has emerged from these data is described. Chapter 8 is a discussion of the 
findings and their significance and the final chapter, Chapter 9, lays out the implications for 




CHAPTER II: REVIEW OF THE LITERATURE 
Historical Literature 
The most recent opioid epidemic in the US. dates to the early 1990s (Inciardi & Goode, 
2003). Around that time, a confluence of circumstances coalesced to drive a dramatic increase in 
the misuse of prescription opioids. These factors included: the rise of the palliative care 
movement and demands to treat pain aggressively; the increasing influence of managed care 
medicine and pressure to keep health care costs down; and increased opportunities for profit-
making by the pharmaceutical industry. These multiple trends collided and reinforced one 
another to drive large increases in opioid prescribing. Between 1996 and 2012, there was a 471% 
increase in the total quantity of opioids prescribed in this country (Axeen et al., 2018). 
The Palliative Care Movement 
Increases in prescription opioid prescribing were in part related to the growth in influence 
of the palliative care movement, which gained a great deal of momentum and visibility in the 
mid-1990s (Zerzan et al., 2006). The use of opioids for the treatment of pain in the terminally ill 
was frowned upon for much of the 20th century (Quinones, 2016). During that time, physicians 
only used opioids under the most controlled circumstances, and with much restraint. However, 
the tide began to turn in the 1970s, when Dr. Cicely Saunders, a nurse at the Saint Christopher’s 
hospice in London began to promote the use of opioids to treat pain in her dying patients, a 
radical idea at the time (Quinones, 2016). The World Health Organization (WHO) embraced the 
idea of humane treatment for the dying patient, and created the WHO ladder, which laid out pain 
treatment steps to be used with terminally ill patients (Zeppetella, 2011). Opioids were 




Increased medical acceptance of the need to treat all pain, not only pain in the terminally 
ill, accompanied the palliative care movement (Zerzan et al., 2006). In addition to embracing 
opioids for the treatment of terminal cancer patients, the WHO went further and, fueled by 
patients’ rights movements, declared that the freedom from pain was a universal human right 
(Quinones, 2016). This declaration opened the door to more liberal uses of opioids to treat pain 
in any scenario. 
Use of Opioids in the Treatment of Pain 
In 1980, Dr. Hershel Jick was a practitioner at Boston University Medical Center 
(BUMC). He and his graduate assistant, Jane Porter, became interested in addiction rates of 
hospital patients and used the hospital database to calculate how many patients become addicted 
after being treated with opioid pain medication as inpatients in the hospital (Zhang, 2017). Dr. 
Jick and Susan Porter wrote a letter to the editor of the New England Journal of Medicine 
entitled “Addiction Rare in Patients Treated with Narcotics” (Porter & Jick, 1980). In this letter, 
the authors reported that of almost 12,000 patients treated with opioids while hospitalized at 
BUMC, only four had become addicted following discharge. The conclusion drawn was that 
“despite widespread use of narcotic drugs in hospitals, the development of addiction is rare in 
medical patients with no history of addiction” (Porter & Jick, 1980, p. 123). 
Data from this study were limited in that they only represented patients receiving opioids 
in an inpatient setting. Nor did the letter include information on how long the course of opioid 
treatment was, what doses were used, or how often pain medications were given. In reality, 
opioids were tightly restricted in hospitals during this time period and were only given out in 
small doses for those in extreme pain (Quinones, 2016). Despite these limitations, this single 
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letter became inordinately influential in the new pain treatment movement, and was cited 
repeatedly for many years to support the claim that the use of opioids rarely resulted in addiction. 
In a recent interview, Jick told a reporter from National Public Radio that when the letter 
was first published in 1980, it was virtually inconsequential. “Only years and years later, that 
letter was used to advertise by new companies that were pushing out new pain drugs…I was sort 
of amazed. None of the companies came to me to talk to me about the letter, or the use as an ad” 
(Hsu, 2017, 0:33). Jick went on to say that pharmaceutical companies used the letter to conclude 
that their new opioids had extremely low addictive properties. During the radio interview, he 
tries to correct the record, stating that this was not at all the intent of the letter and that the 
information had been grossly misinterpreted. 
Recently, a bibliometric analysis of Porter and Jick’s original letter and 608 subsequent 
citations found that: 
 A five-sentence letter published in the Journal in 1980 was heavily and 
uncritically cited as evidence that addiction was rare with long-term opioid 
therapy. We believe that this citation pattern contributed to the North American 
opioid crisis by helping to shape a narrative that allayed prescribers’ concerns 
about the risk of addiction associated with long-term opioid therapy. (Leung et al., 
2017, p. 2194)  
By the early 1980s, Dr. Kathleen Foley at the Memorial Sloane Kettering Cancer Center 
(MSKCC) in New York became one of the leaders of the movement to increase the use of 
opioids for the treatment of pain in the United States. In 1986, Foley, and her colleague at 
MSKCC, Dr. Russell Portenoy, published what would become another influential paper 
(Portenoy & Foley, 1986). In a review of 38 MSKCC patients, they found that only two had 
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become addicted after being treated with opioids, and both of these patients had prior histories of 
substance abuse. The authors concluded that prescription opioids could be prescribed safely on a 
long-term basis without fear of addiction and used the Porter and Jick (1980) study to further 
support their argument. Despite its questionable and limited evidence, the Portenoy and Foley 
paper was widely used to support the increased use of opioids to treat chronic non-cancer pain 
(Kolodny et al., 2015). Years later, Portenoy discredited his own paper claiming that it was based 
on “weak, weak, weak data” (Quinones, 2016, p. 99). Unfortunately, this was years after its 
impact had already been felt.  
At the time, the Portenoy and Foley paper was intensely debated in the medical 
community. Many physicians railed against the idea of using opioids more liberally and 
disagreed with the claim that these were not dangerous and addictive. These ideas ran counter to 
much of the conventional wisdom about the conservative use of opioids that was prevalent at the 
time (Quinones, 2016). Others, including the American Pain Society (APS), embraced the idea 
that the rate of addiction was low when opioids were used to treat pain. In 1995, the APS coined 
the term Pain: The Fifth Vital Sign and began to heavily promote the idea that pain should be 
evaluated by medical practitioners along with blood pressure, pulse, temperature and respiration 
(Quinones, 2016).  
In 1999, the Department of Veterans Affairs implemented a national strategy to improve 
pain management in its health centers called Pain as the 5th Vital Sign (Mularski et al., 2006). 
This strategy required that VA intake nurses assess pain during all outpatient visits. A scale of 0 
to 10 was used, with 10 being the highest pain score; a pain score of 4 or more would trigger 
further assessment and intervention by the healthcare provider (Mularski et al., 2006). In 2000, 
The Joint Commission for Accreditation of Healthcare Organizations (JCAHO) followed suit 
16 
 
and added “the fifth vital sign” to its evaluation of how health care organizations were treating 
patients (Baker, 2017). 
By the mid-1990s, this new approach to treating pain had been firmly established. A 
major premise of the new approach was that “addicts” and “pain patients” belonged in two 
entirely different categories. As a result of these papers claiming low risk of addiction in pain 
patients (Portenoy & Foley, 1986; Porter & Jick, 1980), medical practitioners began to accept the 
idea that opioids could and should be used liberally for the treatment of pain, with no or little risk 
of addiction. A New York magazine article from 2000 illustrates this attitude. 
Research has shown that while pain patients may become physically dependent on 
narcotics to relieve pain, they do not tend to develop aberrant, compulsive, drug-
seeking behavior -- the hallmarks of the largely behavioral and psychiatric 
disorder known as addiction. "With addicts, their quality of life goes down as they 
use drugs," says Fishman. "With pain patients, it improves. They're entirely 
different phenomena.” (DeVita, 2000, para. 30) 
Dr. Scott Fishman, the person quoted above, was Chief of Pain Medicine at UC-Davis 
Medical Center in Sacramento. Dr. Fishman, along with Russell Portenoy and two other leading 
pain doctors at that time, Lynn Webster and Perry Fine, are named as co-defendants in at least 80 
of the 370 federal law suits against opioid manufacturers pending in federal court, as of the 
writing of this manuscript. These cases, brought by cities and counties against opioid 
manufacturers, claim that “key opinion leaders” accepted thousands of dollars from opioid 
manufacturers for research, consulting, honoraria and CME seminars. Plaintiffs suggest that 
these doctors were used by the pharmaceutical industry for “unbranded marketing” and the 
money coming from the industry resulted in “tainted” messaging about pain treatment. They are 
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accused of overestimating the efficacy of these opioid medications and understating their risk 
without good scientific supporting evidence (Parloff, 2018). 
At present, there are few who question the appropriateness of opioid treatment for cancer-
related pain or in the context of palliative care. However, there is much debate over whether 
prescription opioids are effective in the treatment of long-term non-cancer pain (Catan & Perez, 
2012; Chaparro et al., 2013; Eriksen et al., 2006; Manchikanti et al., 2012). Results from the 
2000 Danish Health and Morbidity Survey show that when two groups of chronic pain patients 
are compared, the group receiving long-term opioid treatment reported worse pain, higher health 
care utilization and lower activity levels, compared with matched cohorts of patients not using 
opioids (Eriksen et al., 2006). These authors raise the question of whether the use of opioids in 
the treatment of long-term non-cancer pain is effective for many of those receiving it. In 
addition, they raise the unsettling question of whether this long-term opioid treatment is actually 
making pain worse (Eriksen et al., 2006). Because this was a cross-sectional study, a causative 
relationship between pain relief, quality of life, functional capacity and the regular use of opioids 
could not be determined. In addition, it was not clear what kind of pain treatment the non-opioid 
using group received, if any. However, this study does raise the serious question of whether 
long-term opioid treatment of chronic non-cancer pain is filling any of the key outcomes of 
opioid treatment goals (Eriksen et al., 2006). 
 A Cochrane review of 15 clinical trials that used opioids for the long-term management of 
chronic low-back pain found some evidence that short-term use of opioids was superior to a 
placebo (Chaparro et al., 2013). However, in the studies where opioids were compared to either 
non-steroidal anti-inflammatory drugs or antidepressants, there was no difference in either pain 
or function. These authors caution against using opioids for long-term treatment of chronic low 
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back pain (Chaparro et al., 2013). Unfortunately, there are no longitudinal randomized controlled 
trials on the long-term effects of opioid use in non-cancer pain patients, so there is still much to 
be learned in this area. 
America’s Changing Relationship to Pain 
 Alongside changes in the medical establishment’s approach to pain treatment, came 
changing expectations from patients. An attitude that patients had a right to pain relief and that 
all pain could be treated through the use of medication, as opposed to through a more 
comprehensive bio-psycho-social approach, became the norm (Quinones, 2016). Patients were 
less inclined to take responsibility for their own behavior, and doctors could only suggest, not 
enforce, these interventions. Press Ganey surveys which gauged patient satisfaction with their 
medical care began to be widely used during this time period and physicians became increasingly 
sensitive to their patients’ perceptions of their medical care time (Richard Bolton Siegrist, 2013). 
The surveys served as a subtle pressure on doctors to write prescriptions for opioids, as patients 
were more likely to give a good evaluation to a doctor who provided an opioid prescription. 
Managed Care 
 The managed care movement of the 1980s and 1990s was another factor contributing to 
the increase in opioid prescribing. In an effort to cut costs, health insurance companies were 
growing increasingly reluctant to pay for more expensive kinds of multidisciplinary treatment 
such as physical therapy, occupational therapy or psychological therapy. As a result, doctors 
were deprived of alternative pain treatment strategies at the same time that patients began to 
demand quick and easy pain relief answers (Quinones, 2016). In addition, doctors had less time 
to treat complex pain issues, as they were required to see more patients each day. Studies show 
that as doctors’ visits shortened, prescribing of all medications increased (Quinones, 2016).  
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The Pharmaceutical Industry 
 In 1996, Purdue Pharma began distributing OxyContin, a controlled release semisynthetic 
opioid analgesic (United States General Accounting Office, 2003). OxyContin contains only one 
drug, oxycodone, which is synthesized from thebaine, an opium derivative. Oxycodone is twice 
as strong as morphine, making it a very powerful opioid (United States General Accounting 
Office, 2003). 
 In its original formulation, OxyContin was unique in that it contained an extended-release 
formulation (ER) which allowed for a slow release of oxycodone into the bloodstream over the 
course of the day. This eliminated the need for “clock-watching” and enabled patients to control 
pain with fewer doses each day (Quinones, 2016). Since the extended-release formulation was 
originally intended to provide pain relief over a longer period of time, each pill contained a 
larger amount of oxycodone than an immediate-release formulation (IR). The original 
OxyContin label contained a safety warning that advised patients not to crush the tablets due to 
possible rapid release of this large amount of oxycodone. “OxyContin tablets are to be 
swallowed whole and are not to be broken, chewed or crushed. Swallowing broken, chewed or 
crushed tablets could lead to the rapid release and absorption of a potentially toxic dose of 
oxycodone.” (Pokrovnichka, 2008, p. 6).  Paradoxically, this label may have served as an 
invitation to recreational substance users to do just this. Many OxyContin users crushed the pills 
and then snorted them or mixed them with water and injected them intravenously. 
 In addition, because the extended-release formulation allowed for a delay in absorbing the 
drug, Purdue was allowed to use a special warning label for OxyContin that stated it had a lower 
potential for abuse (Quinones, 2016). This claim became one of the strongest marketing points 
for Purdue, easing physicians’ concerns about prescribing a powerful opioid. Purdue was never 
20 
 
able to cite evidence to support the claim that it had a lower potential for abuse than other 
opioids (Quinones, 2016) and, in fact, the company pleaded guilty in a 2006 court case to falsely 
misrepresenting the addictive properties of the drug (Meier, 2007) and paid a $634.5 million 
fine. 
 At the time of its release, however, Purdue Pharma began an aggressive marketing 
strategy to promote OxyContin, spending $200 million in one year alone on advertising the 
painkiller (Van Zee, 2009). Purdue moved beyond the traditional prescribers of opioid 
painkillers, surgeons and oncologists, to target primary care physicians (Quinones, 2016). 
Physicians who were already heavy prescribers were primary targets, as were nurses, 
pharmacists, hospices, hospitals and nursing homes (Quinones, 2016). Detailers, Purdue sales 
representatives, made direct contact with thousands of prescribers, offering them OxyContin 
“coupons” for patients to use for a one-time free prescription. In addition, physicians were 
inundated with hats, toys, coffee mugs, pens, message pads and music CDs. The company paid 
for trips to resorts in Florida and Arizona where medical practitioners would be wined and dined 
and could attend educational seminars that provided CME credits (Quinones, 2016). 
 There are currently more than 2,500 lawsuits being brought by state and local 
governments against the pharmaceutical industry (Mulvihill, 2020). In the first state trial 
determining whether or not pharmaceutical companies should be held liable for the opioid 
epidemic, the state of Oklahoma won $465 million in a lawsuit against Johnson & Johnson 
(Hoffman, 2019). It is not clear what the outcome of additional cases will be, but it is evident 
that people are beginning to demand that the pharmaceutical industry be held accountable for its 




Early Warning Signs 
Early reports of prescription opioid misuse emerged in rural Maine in the mid-1990s and 
then spread down the East Coast and Ohio into Appalachia (Inciardi & Goode, 2003). Media 
outlets in Maine, Virginia, and West Virginia first began reporting on OxyContin abuse in 2000 
(Angleberger, 2000; Bowling, 2000; Ordway, 2000). Rural communities in Virginia, Kentucky, 
West Virginia and Ohio were particularly impacted during these early years. 
There are several hypotheses as to why these areas were on the front lines of the 
epidemic. One theory is that in these regions, chronic pain was the result of years of manual 
labor in the coal mining, logging, fishing and other blue-collar industries (Inciardi & Goode, 
2003). A disproportionately large number of the population in these parts of the country were 
using strong painkillers regularly (Inciardi & Goode, 2003, p. 19). 
Another hypothesis suggests an economic motivation. When jobs in blue-collar towns 
dried up during these years, residents resorted to public assistance or SSI for income. Both of 
these came with a Medicaid card that provided access to prescription opioids which could be 
sold for several thousand dollars. For income-strapped communities, selling prescription opioids 
became one of the few economic opportunities available (Quinones, 2016). Diverted opioids 
flooded the market and opportunities for misuse escalated as a result. 
In 1990, there were 628,000 new nonmedical users of prescription opioids; by 2000, this 
amount had climbed to 2.7 million annual initiates (Substance Abuse and Mental Health Services 
Administration, n.d.). While there were increases in the nonmedical use of all psychotherapeutics 
during this time (e.g. tranquilizers, stimulants and sedatives), the increase in the nonmedical use 
of opioids exceeded all of these. To this day, opioids continue to be the prescription substance 
most commonly used nonmedically. In 2018, 16.9 million individuals, 6.2% of the population, 
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misused a prescription psychotherapeutic at least once in the past year (Substance Abuse and 
Mental Health Services Administration, 2019b). Of these, 9.9 million misused prescription pain 
killers, 5.1 million misused prescription stimulants, and 6.4 million misused prescription 
tranquilizers or sedatives.  
Empirical Literature 
Age 
In 2018, 9.9 million people aged 12 or older misused a prescription opioid in the past 
year--about 3.6% of the population (Substance Abuse and Mental Health Services 
Administration, 2019b). Within this group, 1.9 million young adults aged 18-25 misused a 
prescription opioid, about 5.5% of all young adults in this age group (Substance Abuse and 
Mental Health Services Administration, 2019b). This number has dropped in recent years from 
almost 9% for young adults in 2015, but nevertheless, it still remains higher than all other age 
groups. 
Race and Ethnicity 
Historically, higher rates of prescription opioid misuse and prescription opioid related 
disorders have been seen among Non-Hispanic Whites than among other races and ethnicities in 
this country (Golub & Johnson, 2005; C. R. Green et al., 2005; Mars et al., 2013; McCabe, 
Morales, et al., 2007; Morrison et al., 2000). In recent years, however, rates for Whites remain 
high, while rates for other ethnic and racial groups have begun to match or even surpass these. 
According to 2013 NSDUH data, 4.2% of the general population (12 or older) acknowledged 
past year misuse of prescription opioids (Substance Abuse and Mental Health Services 
Administration, 2014b). When past year use was broken down by racial and ethnic categories, 
however, higher than average rates were observed for Whites (4.3%), Hispanics (4.5%), 
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American Indian/Alaska Natives (6.9%) and Two or More Races (8.1%). Both Blacks (3.6%) 
and Asians (1.8%) had lower rates than the national average (Substance Abuse and Mental 
Health Services Administration, 2014b). 
In New York City, White New Yorkers have consistently demonstrated the highest rates 
of nonmedical prescription opioid use. Hispanic New Yorkers, however, have had the largest 
change in rates, from 2.2% in 2010-2011 to 5.8% in 2012-2013 (Substance Abuse and Mental 
Health Services Administration, 2012a, 2014a). In 2012-2013, White and Hispanic New York 
City residents reported POM at higher proportions when compared to Black residents (5.1 and 
5.8% versus 3.5%) (Substance Abuse and Mental Health Services Administration, 2014a). 
Prescribing disparities based on race and ethnicity have contributed to greater exposure to 
prescription opioids for Non-Hispanic Whites. In one study of Emergency Department (ED) 
opioid prescribing, non-Hispanic Whites are were more likely to receive an opioid prescription at 
discharge (23% vs 18%) (Pletcher et al., 2008). In another study, patients of different races and 
ethnicities received opioids in similar proportions for fracture diagnoses in the ED (Terrell et al., 
2010) but racial and ethnic disparities were observed for non-fracture diagnoses. Anderson et al. 
(2009) conclude that there is a “persistence of racial and ethnic disparities in acute, chronic, 
cancer and palliative pain care across the life span and treatment settings (e.g., ambulatory, 
inpatient), with minorities receiving lesser quality pain care than non-Hispanic whites” (2009, p. 
1198). 
Perhaps as a result of greater access, non-Hispanic Whites have been at increased risk of 
nonmedical prescription opioid initiation when compared with other racial and ethnic groups. 
This hypothesis, however, does not explain why Hispanics have equally high rates of misuse, as 
this group is also less likely to receive a prescription opioid (Pletcher et al., 2008). 
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 Some initial regional and local research has demonstrated disparities in medication 
availability in neighborhoods with different racial and ethnic composition (C. Green et al., 2004; 
Morrison et al., 2000). Morrison et al. (2000) conducted a study of 347 New York City 
pharmacies in 1998. These authors found that 25% of pharmacies in predominantly non-White 
neighborhoods had sufficient opioid supplies to treat patients in severe pain as compared with 
72% of pharmacies in predominantly White neighborhoods. Reasons provided by these 
pharmacists for having inadequate supplies of opioids included (1) low demand, (2) fear of theft, 
and (3) increased regulatory requirements and governmental oversight. A more recent national 
study, however, examined differences in opioid availability by neighborhood and was not able to 
confirm earlier findings (Hart-Johnson & Green, 2015). This later study sampled 356 pharmacies 
across the country between 2011 and 2014. These authors found no differences in the presence of 
individual medications by neighborhood racial or ethnic composition (Hart-Johnson & Green, 
2015). Clearly more research is necessary here to understand how ethnicity, race, and 
neighborhood affect nonmedical prescription opioid initiation and subsequent use. 
Biological Sex and Gender 
Studying gender in the context of addiction is a complex endeavor. Sex is generally 
understood to be the mostly unchanging biological makeup of being male or female (Phillips, 
2005). Gender, on the other hand refers to a combination of socially constructed roles and 
expectations that a given society attributes to men or women and ultimately refers to the sex with 
which an individual identifies (Lasopa et al., 2015). Gender is a social rather than a biological 
construct, however it is nearly impossible to examine these variables as independent of one 
another as they interact continuously throughout the life cycle (Phillips, 2005). To the extent 
possible, this study has focused on gender as a social construct, although in some cases, findings 
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that seem to be strongly influenced by the interplay between biological sex and social constructs 
of gender are identified. For example, opioid prescribing for women seems to be influenced by 
both biological factors associated with sensitivity to pain and the socially constructed meaning 
that contributes to pain tolerance and legitimacy of seeking medical support for the treatment of 
pain.  
Data regarding gender differences in prescription opioid misuse are mixed. Generally, 
men have higher rates of use, abuse and dependence for most substances when compared with 
women (Compton et al., 2007; Kessler et al., 2005). However, several studies have found that 
women are more likely than men to use prescription opioids nonmedically (J. P. Kelly et al., 
2008; Simoni-Wastila, 2000; Simoni-Wastila et al., 2004). An early population-based study 
using 1991 data from the National Household Survey on Drug Abuse (NHSDA) showed that 
female gender increased the likelihood of POM by 41% (Simoni-Wastila et al., 2004). Other 
population-based studies have also reported higher percentages of women than men using 
prescription opioids (J. P. Kelly et al., 2008; Simoni-Wastila, 2000). Other researchers have 
found equivalent rates for POM between men and women (Blanco et al., 2007; T. C. Green et al., 
2009; McCabe, West, et al., 2007; Zacny et al., 2003) or higher rates for men (Becker et al., 
2008; Carise et al., 2007; Tetrault et al., 2008). 
Some of these discrepancies could be attributable to differences in settings, sources of 
data, types of prescription opioids assessed and varying definitions of the term “prescription 
opioid misuse” (Back & Payne, 2009). It is also possible that these are not a result of 
methodological differences but instead reflect changes in gender use patterns over time. As 
prescription opioid misuse expands, its profile begins to look more like patterns of illegal 
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substance use where men have historically shown higher rates of use (B. C. Kelly et al., 2013; 
Tetrault et al., 2008). 
When taking age into consideration, the picture becomes even more complex. Colliver 
and colleagues (2006) examined gender differences in relation to specific age cohorts and found 
that the percentage of adolescent girls (12-17) who are misusing prescription opioids was double 
that of boys of the same age (.8% vs. 1.4%). However, by the time they enter young adulthood 
(18-25), men begin to surpass women (1.4% vs. 1.1%). These findings point to a possible 
heightened time period of vulnerability for adolescent girls. 
When looking at sources of prescription opioids, the differences between men and 
women are significant. Beginning with the experience of pain, a range of sex-based factors may 
have an impact on women’s use of prescription opioids. There is some preliminary evidence that 
demonstrates women’s higher sensitivity to pain (Keogh, 2006). In addition, sex-specific 
differences have been located in opioid receptors resulting in the need for greater doses for 
women to achieve the same analgesic effect (Soldin et al., 2011). In addition, because of smaller 
body mass in relation to men and differences in metabolism of opioids, some postulate that the 
therapeutic window of opioids for women might be smaller leading to a greater likelihood of 
experiencing dependency and withdrawal symptoms (Soldin et al., 2011). In general, women 
report more chronic pain, greater intensity of pain and more sensitivity to pain than men 
(Foreman, 2014). In terms of gender-related factors, sensory experiences of pain are shaped by 
cultural and social expectations and gender-related socialization may play a significant role in 
how women experience pain and how comfortable they feel expressing this pain and therefore 
may shape women’s use of prescription opioids in complex ways (Hemsing et al., 2016). 
Access to prescription opioids also can be viewed through a gender lens. Women make 
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more frequent visits to health care providers than men (Canadian Centre on Substance Abuse, 
2013). Women are 41% more likely to receive a prescription for an opioid (Cicero et al., 2009; 
Hirschtritt et al., 2018; Simoni-Wastila, 2000), and physicians prescribe higher doses of opioids 
to women more frequently (Kelly-Blake, 2013). Women misusing prescription opioids perceive 
them to be safer and less stigmatized than other substances, particularly illicit ones (Tuchman, 
2010). In a treatment-seeking sample, women reported obtaining opioids primarily from their 
own prescriptions, family members, friends or acquaintances, while men were more likely to 
obtain opioids from dealers (T. C. Green et al., 2009).  
Genetic Predisposition 
 It is important to briefly acknowledge the role of genetics in the current understanding of 
the etiology of addiction. Overall, using family, adoption and twin studies, addiction researchers 
have found that genetic predisposition for the population at large accounts for roughly 50% of 
vulnerability to addiction (Hamilton & Nestler, 2019; Uhl et al., 2011). In addition, researchers 
have found that most of the heritable influence is not substance-specific (Uhl et al., 2011). That 
is, genetic predisposition for addiction creates a vulnerability to developing an addiction to any 
substance or multiple substances, rather than just one specific substance. And finally, there 
seems to no single gene that accounts for this genetic predisposition but rather a group of genes 
(Uhl et al., 2011). 
 Also relevant here is the understanding of how the study of epigenetics--gene and 
environment interactions--can impact substance use outcomes. All humans have an individual 
genome and an epigenome; the epigenome is the way that the genome is wrapped around protein 
bodies (Kumpfer, 2014). Stress can impact how tightly the genome is wrapped, leading to 
differing expressions of the same genome. This is demonstrated in studies where identical twins 
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develop differently despite having identical genomes. Recent studies with mice have shown that 
nurturing parenting might be one of the most critical variables in preventing the manifestation of 
genetic diseases (Kumpfer, 2014). In these studies, a nurturing parent reduces stress and cortisol 
that “turn on” or “turn off” inherited genes. As the study of epigenetics is developed, the “nature 
vs. nurture” debate has begun to recede (Traynor & Singleton, 2010). Increasingly clear is the 
idea that in addiction, nature and nurture are shaped by and shape each other on an ongoing basis 
in a complex and multidimensional manner (Egervari et al., 2018). 
Unfortunately, there has been little research on epigenetic differences between males and 
females in addiction research. Most preclinical studies on the epigenetics of opioid use have 
studied male rodents exclusively, leaving an enormous gap in our understanding of sex and 
gender differences and plenty of room for further investigation (Browne et al., 2020). Kumpfer 
(2014) has hypothesized that a large percentage of the genes that contribute to the manifestation 
of addiction are located on the sex-linked chromosome. If this is the case, women would have to 
inherit these “addiction genes” from both sides of the family in order to manifest the disease, 
whereas males would only have to inherit genes from one side. While this research is still in its 
infancy, it is useful to keep in mind when thinking about sex, gender and vulnerability to 
addiction.  
While genetic influence and the influences of gene-environment interactions were not the 
focus of this study, their significance must be acknowledged. Understanding that roughly half of 
the likelihood of developing problematic substance use comes from a genetic vulnerability must 





 Research on substance use initiation has found that men tend to initiate substance use with 
other men and that women also generally initiate with men (Ettorre, 1992; Powis et al., 1996; 
Rosenbaum, 1981; Taylor, 1993). In studies with injection drug users, women seem to have been 
particularly influenced by a male sexual partner’s injection risk behavior (Bryant & Treloar, 
2007). Women were more likely to be introduced to injection by a male sexual partner; 51% of 
female heroin users were injected by their male partner at a first injection event (Powis et al., 
1996). This is compared to 90% of male heroin users who were injected by a friend at a first 
injection event (Powis et al., 1996). Some explained these findings by suggesting that women are 
pressured to participate in substance use by men, particularly in the case of a sexual partner 
(Anglin et al., 1987; Reed, 1985). 
Others have challenged this view, finding that, on the contrary, women are actively 
involved in the decisions to initiate substance use (Maher, 2000; Rosenbaum, 1981; Taylor, 
1993). Rather than being victims of social pressure by male partners, they are actually 
“purposeful participants” (Payne, 2007). Tuchman (2015) interviewed 26 women between the 
ages of 22 and 63 (mean = 43.2) who were injection drug users (IDU). In this small qualitative 
study, Tuchman found that participants were largely influenced to transition to injection drug use 
by other women and more than half of the sample received her first injection from a woman in 
her social network, not a male sexual partner. Women who were able to self-inject displayed a 
great deal of agency around the context of their use, including safety and risk management. 
Rigg and Murphy (2013) identified several “storylines” for nonmedical prescription 
opioid initiation in their South Florida study of 90 people between the ages of 18 and 51 (mean = 
31). They found one specifically gendered path to POM initiation which they refer to as “A Male 
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Influence” (Rigg & Murphy, 2013). In this pathway, women were typically introduced to 
prescription opioids via close contact with a male who was already using these substances--the 
initiation frequently occurred within a romantic heterosexual relationship. Women described 
these relationships as “tumultuous and rife with dysfunction and drug use” (Rigg & Murphy, 
2013, p. 969). Women were often adolescents or young adults when they began dating these men 
who introduced them to the novelty and excitement of this lifestyle (Rigg & Murphy, 2013). 
These findings suggest that intimate relationships for women can be an important factor in the 
context of nonmedical prescription opioid initiation but that this is not necessarily always the 
case. 
Family 
Familial factors can have significant impacts on young people’s substance use. For both 
genders, exposure to parental substance use disorders and inadequate or inappropriate parental 
discipline or supervision are associated with increased risk of substance use (Biederman et al., 
2000; David et al., 1992). Several studies have found an association between parental factors and 
nonmedical prescription opioid use. Adolescents living in two-parent households were 
significantly less likely to report POM  (Schepis & Krishnan-Sarin, 2008). Low parental 
involvement has been positively associated with POM use (Sung et al., 2005). This research all 
comes from studies with adolescents, however, and it is not clear whether these factors continue 
to be influential for young adults. In addition, these studies do not, for the most part, discuss 
gender-specific risks. Again, more research is necessary in this area to understand the particular 






An important dynamic involving peer influence on substance use involves perceived 
substance use norms. The research on the influence of substance use norms by young adults is 
inconsistent (Stone et al., 2012). For example, some studies have shown that young adult college 
students’ perceptions of “normal” drinking behavior on campus can affect drinking behavior and 
problematic use, particularly among young men (Read et al., 2002). Other studies have shown 
that perceived group drinking norms do not affect drinking behavior (Wechsler et al., 2003) 
among college students. Wechsler et al. (2003) suggest that small peer group norms might have a 
more powerful impact than college-wide drinking norms in this group. These studies were 
conducted on young adults in relation to alcohol use behavior. Research is needed in order to 
understand how perceived norms influence POM use initiation, particularly among young 
women. 
Income 
Substance use in general is highly correlated with income (Faupel et al., 2013). As the 
price of a substance increases, use of the substance generally decreases (Faupel et al., 2013). 
Black market prices of prescription opioids have fluctuated greatly over the last 20 years. As 
policy changes have targeted increases in use, supplies of illicit prescription opioids have 
decreased and prices have increased (Kolodny et al., 2015). Price has been shown to be an 
extremely relevant factor in a users’ decision to transition from prescription opioids to heroin. 
Qualitative studies have found that the transition from prescription opioids to heroin is related to 
heroin being less costly, more available, and more potent than prescription opioids (Canfield et 





Increased availability of a substance has been found to create increased demand for the 
substance when there is high potential for abuse (Inciardi & Cicero, 2009). Where there is an 
increase in therapeutic exposure to prescription opioids, as measured by prescription opioid 
prescriptions filled in a given zip code, there is a corresponding increase in abuse of that 
substance in that region (Cicero et al., 2007). 
Overdose rates involving prescription opioids correlate closely to the rates of prescription 
opioids filled. In 2008-2009, four neighborhoods in Staten Island and one in Queens were found 
to have the highest rates of oxycodone and/or hydrocodone prescriptions filled (Paone et al., 
2011). Of these neighborhoods, four of the five also had the highest rates of prescription opioid 
overdoses during the same time period (Paone et al., 2011). Rates of prescription opioid-involved 
overdoses in 2013 were highest in the lowest poverty (wealthiest) neighborhoods (4.1 per 
100,000 residents) followed by the second highest rate in the highest poverty neighborhoods (3.3 
per 100,000) (Paone et al., 2014). Paradoxically, prescription opioid-involved mortality rates in 
New York City seem to support research that finds high levels of substance use in very wealthy 
and very poor communities. In sum, the relationship between POM and income is polarized. 
Overall, Staten Island residents had the highest rates of filled opioid analgesic 
prescriptions (131 per 1,000 residents) when compared with residents of other New York City 
boroughs (106/1000--Manhattan; 99/1,000--Bronx; 79/1000--Queens; and 74/1000--Brooklyn) 
(Tuazon et al., 2013). 
Heroin 
Prescription opioids were widely available in Staten Island, particularly in the early days 
of the epidemic between 2000 and 2010. During this decade, awareness slowly increased 
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regarding the problematic consequences of the large amounts of opioids that were being 
prescribed. But it was not until 2010 that major policy initiatives were introduced both nationally 
and locally to address growing concerns. The reformulation of OxyContin in 2010, for example, 
made it harder to crush and inject one of the most desirable prescription opioids available. On a 
local level, New York State implemented the iStop program in 2013. iStop is a prescription 
monitoring program which mandates all prescribers in New York State to check a patient’s 
prescription history prior to prescribing a controlled substance such as an opioid (Allen et al., 
2019). 
Theoretical Literature 
Ecological Systems Theory 
 One of the two major theoretical frameworks informing this study is ecological systems 
theory. Social scientists have embraced ecosystems theory for decades, as it offers a powerful 
theoretical framework for understanding individuals, families, communities, organizations, and 
societies. At the core of ecosystems theory is the belief that people both affect and are affected 
by physical, social and cultural influences from the surrounding environment. 
 Social epidemiologists Katherine Keyes and her colleagues at the Mailman School of 
Public Health at Columbia University have developed a model of substance use risk factors that 
is grounded in ecosystems theory. Using ideas from Urie Bronfenbrenner’s bioecological model 
(2005), Norman Zinberg’s Drug, Set and Setting (1984) and ecosocial theory (Krieger, 2001), 
Keyes et al. have developed a framework for conceptualizing the etiology of illicit substance use 
(2014). These researchers suggest that substance use can be understood by examining three 
layers of influence, micro, local-context and macro, and the interactions between these layers.  
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 Keyes et al. (2014) define the micro level as a set of endogenous factors such as genetic 
vulnerability, neurobiological factors, pharmacological reactivity, personality traits, psychiatric 
morbidity, gender, race, ethnicity and age can all influence substance use behavior. In addition, 
the pharmacological properties of the class of substance itself is crucial in understanding 
motivation for use, how it is used and who is likely to use it. Because they are primarily 
addiction researchers, Keyes et al. have taken into account the key variable of the substance itself 
in their model, making it particularly useful for understanding substance use behavior. At the 
local context level, the authors discuss two major sources of influence: family and peers. Family 
context includes family composition, family stressors, and dynamics. Peer influence includes 
peer pressure, social position, and peer deviance. At the macro level, the authors include relevant 
structural factors such as the availability of substances, the norms around substance use, 




Figure 1. A Conceptual Framework for the Etiology of Illicit Drug Use. Reprinted from 
"Understanding the Rural-Urban Differences in Nonmedical Prescription Opioid Use and 
Abuse in the United States," by K. M. Keyes, M. Cerdá, J. E. Brady, J. R. Havens and S. 
Galea, 2013, American Journal of Public Health, 104(2), p. 53.  
 
Relational Theory 
 The other theoretical perspective that informs this study is relational, or self-in-relation 
theory. Originally developed at the Stone Center at Wellesley College in the 1980s, relational 
theory suggests that connection with others is a basic need for all humans, and that this 
connection is particularly important for women (Jordan et al., 1991). Based on the work of 
feminist theorists (Chodorow, 1978; Gilligan, 1982; Miller, 1976), relational theorists challenged 
conventional developmental theory that pathologized women’s need for connection. They 
suggested that, for women, forming human connections was a foundation of healthy 
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development and that a lack of healthy connections could result in psychological problems 
(Covington & Surrey, 1998; Jordan et al., 1991). Substance misuse is one such psychological 
problem that can develop as a consequence of this disconnection (Covington & Surrey, 1998). 
For some women, substances are used to initiate or maintain connections with others (Covington 
& Surrey, 1998). For others, substances are used to cope with the stress associated with 
unhealthy and disconnected relationships (Byington, 1997). Regardless, relationships to 
substances can evolve to replace connections with humans, and often come to be treated as 
essential despite negative consequences (Byington, 1997). The relationship with the substance 
becomes central to the woman’s life and serves as a solution to feelings of disconnection while 
simultaneously contributing to further disconnection (Covington & Surrey, 1998). In this study, 
relational theory is used to understand behavior within the local context or interpersonal domain, 
where it’s application is most relevant.  
Gaps in the Literature 
As demonstrated above, a substantial body of research has characterized the 
epidemiological profile of the current epidemic and initiation of prescription opioids among 
young adults. In addition, the two theoretical frameworks discussed could prove to be useful in 
understanding these data. There are, however, gaps in both the empirical and theoretical 
literature. There has been scant attention paid to gender-specific or gender-sensitive factors 
involved in women’s initiation to prescription opioid misuse or in theoretical models that aid in 
our understanding of this social process. This remains an understudied area, despite the fact that 
women have high levels of prescription opioid misuse and prescription opioid use disorders, are 
more likely to report this use upon admission to substance abuse treatment, and have increasing 
rates of prescription opioid-involved overdoses. In addition, most research addressing gender-
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specific factors is epidemiological in nature, focusing on demographic trends and risk factors for 
opioid use disorders. There is a critical lack of research capturing the subjective experiences of 




CHAPTER III: RESEARCH METHODOLOGY 
The purpose of this study is to increase our understanding of the social processes 
involved in young adult women’s initiation of nonmedical prescription opioid use in Staten 
Island, NY. Research focusing on the subjective experiences of these young women informs the 
development of gender-sensitive prevention and treatment efforts for this vulnerable group. The 
central research question concerns the social processes involved in the initiation of nonmedical 
prescription opioid use for this group. Sub-questions focus on (1) how participants describe their 
initiation experiences; (2) ways that participants experienced family, peer and intimate 
relationship contexts as influencing these initiation experiences; and (3) what role, if any, did 
race, class or ethnicity play in these initiation experiences. 
This chapter describes the research methodology and covers the following areas: 
rationale for the research approach; sampling and recruitment; data collection; data analysis; 
human subject issues; reflexivity and role of the researcher; and rigor. 
Rationale for the Research Approach 
The study is a cross-sectional, exploratory study using qualitative data collection and 
analytic methods. A small amount of quantitative data was also collected in order to capture 
demographics and basic substance use history. Qualitative methodology is appropriate when 
little is known about the topic, the question is complex and of emotional depth, and the 
researcher seeks to capture the lived experience of individuals experiencing particular 
phenomena (Padgett, 2016). This study meets all of the above criteria. First, little is known about 
initiation experiences of young women who engage in prescription opioid misuse. Second, the 
subject is sensitive and of emotional depth. And finally, other methods, such as the use of a 
survey instrument, would not have captured the lived experiences of participants in sufficient 
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depth. A deeper and more comprehensive understanding of prescription opioid use initiation 
requires a methodology that is able to capture how these women themselves understand and 
describe this experience. 
This study uses the grounded theory qualitative tradition. Glaser and Strauss define 
grounded theory as “the discovery of theory from data systematically obtained from social 
research” (1967, p. 2). While primarily concerned with constructing abstract theoretical 
explanations of social processes, grounded theory provides clear guidelines for systematically 
collecting and analyzing data while still maintaining flexibility (Charmaz, 2014). 
In addition, this study assumes a constructivist epistemology. Much of substance use 
research draws on a positivist epistemology that too often disregards the privileges and 
preconceptions that shape all phases of inquiry, such as research questions, study aims, data 
analysis and the interpretation of findings (Charmaz, 2014). Constructivist grounded theory uses 
traditional grounded theory strategies, but rejects assumptions of an objective external reality and 
a neutral observer, embracing instead the idea that the researcher brings her own constructions of 
reality to the research process. This approach, therefore, entails an examination of the 
researcher’s own experiences and how these shape the research questions, methods, analyses, 
and conclusions (Charmaz, 2014; Clarke, 2003). In this study, the perspective and privilege that 
the researcher brings is made visible and it is understood that the findings represent subjective 
and intersubjective constructions of reality, not exact representations of it. 
The constructivist grounded theory tradition utilized in this study necessitates an 
interpretive approach. This study examines what happened, how it came about, and how the 
participants come to understand this experience. How do they explain what happened? How does 
this explanation of initiation impact their behavior in the future? 
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In addition, constructivist grounded theory acknowledges the role that the researcher 
plays in the interpretation of the data: “all knowers are embodied and that embodiment is 
inscribed on the knowledge produced” (Clarke et al., 2017, p. 42). The grounded theory is 
embedded in the researcher’s perspective; it doesn’t stand outside of it (Charmaz, 2006). In this 
study, the researcher has continuously monitored this through reflection and memoing. The 
choice of topic, research questions, research site, data collection, data analysis and theory 
building were all filtered through this particular researcher’s belief systems, experiences and 
perspectives.  
Finally, interpretive inquiries seek to understand not only what we can understand but 
what we should be striving to understand (Clarke et al., 2017, p. 42). This has important 
implications for social work researchers in particular who are conducting research within the 
code of ethics of the profession. One of the six core values of the social work profession, as 
defined by the NASW Code of Ethics, is the promotion of “social justice and social change with 
and on behalf of clients” (National Association of Social Workers, 2008). Research in the 
context of the profession’s value system requires us to look for “what has gone and goes 
unstudied, sites of particular tensions of omission…” Hess (2009) refers to this as “undone 
science”, or scientific research that is ignored and unfunded. Social Workers must look for areas 
of scientific inquiry that promote social justice, that is “the full and equitable participation of 
people from all social identity groups in a society that is mutually shaped to meet their needs” 
(Adams & Bell, 2016). As Susan Star says: “grounded theory is an excellent tool for 






Sampling and Recruitment 
Staten Island was chosen as the research site due to the high rates of prescription opioid 
misuse and overdoses in recent years. Participants were purposively recruited from all over 
Staten Island. Purposive sampling is “a deliberate process of selecting respondents based on their 
ability to provide the needed information” (Padgett, 2008). The principal investigator shared 
information about the study with municipal leaders, community coalitions, substance use and 
mental health treatment professionals, LGBTQ service organizations, self-help groups, harm 
reduction organizations and social-service and criminal justice facilities. The researcher also 
distributed flyers (see Appendix A) in laundromats, parks, libraries, post offices, college 
campuses and transit hubs such as the Staten Island ferry terminal and bus and subway stops. 
Online recruitment consisted of sharing information with online support groups for prescription  
opioid misuse. 
Three of the study participants were recruited via snowball sampling, where research 
participants who had already completed the study referred other participants (Shaw & Holland, 
2014). Snowball sampling is often utilized in research when members of a population are 
difficult to access (Barendregt et al., 2005; Biernacki & Waldorf, 1981). 
Criteria for participation in the study included the following: 
• Women between the ages of 18 and 34 at the time of the interview 
• Initiation of nonmedical use of prescription opioids in Staten Island, NY 
• Nonmedical use of opioids took place prior to initiation of heroin use (if heroin 
use had occurred) 
• A history of an Opioid Use Disorder diagnosis 
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According to the most recent edition of The Diagnostic and Statistical Manual of Mental 
Disorders, an opioid use disorder is diagnosed if there is a “problematic pattern of opioid use 
leading to clinically significant impairment or distress…occurring within a 12-month period” 
(American Psychiatric Association, 2013). Substance use disorders are located on a continuum of 
mild to severe based on the number of symptoms an individual endorses. Symptoms include the 
following:  
1. Opioids are often taken in larger amounts or over a longer period than was intended. 
2. There is a persistent desire or unsuccessful efforts to cut down or control opioid use. 
3. A great deal of time is spent in activities necessary to obtain the opioid, use the 
opioid, or recover from its effects. 
4. Craving, or a strong desire or urge to use opioids. 
5. Recurrent opioid use resulting in a failure to fulfill major role obligations at work, 
school, or home. 
6. Continued opioid use despite having persistent or recurrent social or interpersonal 
problems caused or exacerbated by the effects of opioids. 
7. Important social, occupational, or recreational activities are given up or reduced 
because of opioid use. 
8. Recurrent opioid use in situations in which it is physically hazardous. 
9. Continued opioid use despite knowledge of having a persistent or recurrent physical 
or psychological problem that is likely to have been caused or exacerbated by the 
substance. 
10. Tolerance, as defined by either of the following: 
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a. A need for markedly increased amounts of opioids to achieve intoxication or 
desired effect. 
b. A markedly diminished effect with continued use of the same amount of an 
opioid. 
11. Withdrawal, as manifested by either of the following: 
a. The characteristic opioid withdrawal syndrome. 
b. Opioids (or a closely related substance) are taken to relieve or avoid 
withdrawal symptoms. (American Psychiatric Association, 2013) 
For this study, a participant qualified for an Opioid Use Disorder if they endorsed at least 
four out of eleven of the above criteria for any 12-month period. 
Individuals who saw the flyers and were interested in being screened for participation 
contacted the principal investigator by phone or text message. Once initial contact was made, a 
screening phone call was scheduled. During the screening call, eligibility was established (see 
Appendix B). If the individual met criteria for inclusion in the study, a mutually convenient 
location and date for the interview was established. 
Data Collection 
Interviews were structured, semi-focused, and conducted in person by the principal 
investigator; interviews lasted between 30 minutes and an hour. Interviews took place in a 
private confidential location. Participants were provided with a $25 gift card as an incentive for 
participation and a MetroCard to cover transportation costs. All interviews were audio-recorded 
and then transcribed verbatim by a transcription service. Non-verbal data was collected by the 
interviewer and recorded via memos after each interview. This non-verbal data included 
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information about the setting, body language, and interaction style which enhanced the verbal 
data captured in the interview transcript (Charmaz, 2014). 
An interview guide (see Appendix C) was used to provide the interviewer with a set of 
standard questions to ensure that certain content areas were covered with all participants. At the 
same time, the semi-structured nature of the interview allowed the interviewer to pursue topics 
that were not included in the protocol but that seemed relevant and interesting (Padgett, 2008). 
This flexible interviewing approach provided the opportunity to uncover unanticipated areas of 
significance. 
Data Analysis  
A crucial component of data analysis in the grounded theory tradition is the iterative 
process of data collection and data analysis. Referred to by Glaser and Strauss (1967) as the 
constant comparative method, early analytical ideas are used to inform areas of inquiry for future 
interviews (Creswell, 2014). As data is collected, categories of information are clarified and 
refined (Charmaz, 2006; Corbin & Strauss, 2007).  
A transcription service was used to transcribe all audio interviews. Once interviews were 
transcribed, the researcher reviewed each transcript while listening to the audio interview to 
ensure that transcription was accurate. After this verification, the principal investigator began the 
coding process. All transcripts were uploaded into Dedoose, a web application for managing, 
analyzing, and presenting qualitative and mixed method research data (Dedoose Version 8.1.8, 
2018).  
 Coding is a crucial component of grounded theory data analysis. Codes serve as the link 
between the raw data and the emerging theory (Charmaz, 2014). Coding in this study took place 
in two different phases, the initial phase and the focused phase (Charmaz, 2014). Initial coding 
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involved applying a code to each segment of data (Glaser, 1978). In this case, the researcher 
employed a line-by-line coding strategy, which involved creating codes for each line of the 
transcribed interviews. This coding strategy allows the researcher to stay very close to the data, 
facilitating the identification of research participants’ implicit concerns in addition to explicit 
comments (Charmaz, 2014) 
 In keeping with Charmaz’s (2014) coding guidelines, initial codes were active and 
written in gerund form, emphasizing actions and processes happening in the data. Charmaz 
(2014) stresses that staying as close as possible to the participants’ meanings and actions 
encourages the researcher to reflect the insider’s perspective as opposed to an outsider’s 
perspective. Examples of some initial codes were “feeling instant attraction to opioids,” “not 





Initial Code Focused Code Thematic Category 
Feeling instant attraction to opioids Oh Wow, I Like These First POM Event 
Friend giving me a pill My First Time First POM Event 
“Liking” opioids when prescribed Pain Pills Individual Context 
Not knowing pills were addictive We Didn’t Know Interpersonal Context 
Not recognizing signs of withdrawal That’s When I Knew I Had a 
Problem 
Problem Recognition 
Nobody knowing about my use It’s Very Quiet Maintenance 
 
The next stage of coding in this study consisted of focused coding where the researcher 
elevated initial codes that had the greatest analytical significance into thematic categories. 
During focused coding, the initial code “feeling instant attraction to opioids” became “Oh Wow, 
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I Like These.” The initial code “not knowing pills were addictive” became “We Didn’t Know.” 
“Friend giving me a pill” became the focused code “My First Time.” 
Once focused codes were developed, the researcher collapsed them into Thematic  
Categories (see Table 1)—the focused code “Oh Wow, I Like These” became a subtheme under 
“First POM Event”. The focused code “We Didn’t Know” became a subtheme under 
“Interpersonal Context.” Finally, the focused code “My First Time” became a subtheme under 
“First POM Event.” 
In addition to coding, the researcher used visual charting to aid in analysis. Early in the 
process, these visual diagrams helped to capture initial thinking about the data being collected in 
relation to the study question and the extant literature. Later on in the process, charts helped to 
map findings as a way of generating meaning out of data chunks and to discern patterns. This 
facilitated the development of a substantive theory of POM initiation among these women. 
Ethical Conduct of the Research 
 IRB approval was obtained prior to data collection, and the study was conducted in a 
manner fully compliant with accepted ethical standards of human subjects research and the Code 
of Ethics of the National Association of Social Workers (National Association of Social 
Workers, 2008). Prior to the beginning of each interview, participants reviewed the purpose and 
procedures of the study, the voluntary nature of the study, financial compensation and the 
protection of confidentiality before verbally consenting to participation in the study (see 
Appendix D). A waiver for written consent was obtained from the IRB in order to further protect 
the confidential nature of information related to illegal activities. No identifiable information 
(e.g., name, date of birth, address) was collected. A coding system was used to keep track of the 
participants and the interviews conducted, and all interviewees were assigned an alias upon 
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completion of the interview. At the end of each interview, the researcher provided a list of 
community resources that participants could access if they were in need of further support (see 
Appendix E).  
Reflexivity and Role of the Researcher 
 Qualitative research generally assumes that researchers are inherently biased, and 
represents an epistemological stance that does not pursue hypothetical distance or objectivity 
(Padgett, 2008). The researcher’s acknowledged subjectivity is, however, managed through 
reflexivity, the active self-monitoring of one’s own subjective position, an integral part of any 
qualitative research endeavor. I came to this study with my own preconceptions that presented 
both strengths and challenges. My professional experience includes many years of working with 
those who misuse substances and provided me with a keen sensitivity to these substance misuse 
experiences. On the other hand, this fluency might have predisposed me to expect certain 
information from the data and not have allowed me to hear unexpected or unfamiliar material. 
My knowledge of the empirical and theoretical literature in this area enriched my understanding 
of substance misuse behavior, while at the same time narrowing my openness to “out of the box” 
thinking. Finally, I came to the study with my own positionality as a middle-class, middle-aged, 
White, Jewish woman living in Brooklyn, New York who has not personally had an experience 
of prescription opioid misuse. These identities certainly influenced my analysis of the data in 
both overt and covert ways. 
Throughout this study, I monitored my preconceptions through memoing and worked to 
remain aware of them and checked that they were not interfering with the emerging analysis. A 
personal strength in this area includes my professional background as a clinician, which has 
involved many years of introspection and self-reflection built into my professional practice. As a 
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result, I felt particularly prepared to engage in work that demands a high level of self-awareness 
and reflexivity.   
Trustworthiness and Rigor 
The PI employed several different strategies for increasing trustworthiness and rigor, 
including analytic triangulation (Padgett, 2016). This type of triangulation helps to safeguard 
against bias in the interpretation of data by having two people independently code transcripts and 
then meet to develop a working list of codes for subsequent transcripts. In this case, the PI 
invited a PhD doctoral student with experience in grounded theory coding to co-code two 
interview transcripts during the early stages of the project. This co-coder had no background in 
this content area prior to working on the study, lending an additional level of rigor in the form of 
cross-disciplinary diversity. 
The co-coder’s initial codes were compared with the initial codes generated by the 
principal investigator and reconciled for consistency. There was a high level of consistency 
between the PI’s codes and the co-coders codes. For example, both coders developed initial 
codes such as: “feeling instant attraction to opioids,” “not recognizing signs of withdrawal,” and 
“nobody knowing about use.” 
In addition, the co-coder’s nascent analysis highlighted several thematic areas that had 
begun to appear in the interviews. These thematic areas ended up being prominent themes in the 
final analysis once all interviews had been coded. Some of these early thematic impressions from 
the co-coder were: easy access to opioids; multiple opportunities for substance use in the 
park/woods; extensive histories of substance use in families of origin, first time use facilitated by 
a close friend; history of social trauma; stress and burden of multiple responsibilities such as 
work and parenting; and inconspicuous user. As a result of this co-coding work, initial codes and 
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preliminary thematic constructs were developed and reconciled for consistency, an effort that 
served to enhance the trustworthiness and rigor of the later analytic work. 
 In addition, an audit trail was maintained via analytic memos throughout the study, which 
aided in transparency about each step in the process of data collection and analysis (Lincoln & 
Guba, 1985). In grounded theory, memo-writing is used to capture thoughts, impressions, and 
analytic insights as they occur. Memo-writing promotes the exploration of emerging ideas about 
the data, and helps the researcher engage in reflexivity and examination of personal bias 
(Charmaz, 2014). 
This chapter reviewed the research methodology and covered the following areas: 
rationale for the research approach; sampling and recruitment; data collection; data analysis; 
human subject issues; reflexivity and role of the researcher; and rigor. Chapters 4, 5 and 6 




CHAPTER IV: INDIVIDUAL CONTEXT 
 Chapters 4, 5, and 6 present the research findings. This study uses Keyes et al. (2014) 
conceptual framework presented in Chapter 2 (Figure 1) as a way to organize findings into three 
levels of influence. Chapters 4 and 5 will discuss factors that influenced initiation of POM at 
these three levels--individual, interpersonal and community. Chapter 6 describes the initiation 
trajectory from the source of the prescription opioids and the first misuse event to problem 
recognition and maintenance. A conceptual model of how these findings interact with one 
another is presented in Figure 2. below. 




This chapter covers the individual context and begins with an overview of participant 
demographics. It then goes on to present findings related to both opioid and other psychoactive 
substance exposure prior to POM, history of emotional and physical pain, mental health history, 
stress, and genetic predisposition. Together this collection of factors contributed to the creation 
of a vulnerability to prescription opioid misuse and subsequent opioid use disorders among this 
group. 
Participants 
The sample consisted of 14 women between the ages of 21 and 34. The mean age was 29 
with a standard deviation of 4.69. All participants identified as cisgender females, that is, their 
gender identification aligned with their biological sex. Twelve participants identified as white, 
two as multi-racial. One woman identified as gay/lesbian, the rest identified as heterosexual. All 
but one participant graduated from high school; nine had completed some college; and one had a 
Master’s degree. This demographic information is captured in Table 2 below. 
Table 2 
Participant Demographics 
Pseudonym Age Race Ethnicity Sexual 
Orientation 
Education 




Felicia 34 White/Hispanic Italian/Puerto Rican Heterosexual College 
Molly 33 White Irish Heterosexual Some 
college 
Nadine 33 White Irish-Italian Heterosexual H.S. 
Diploma 
Jessica 32 White Italian/Irish/Scottish Gay/lesbian College 
Samantha 32 White White American Heterosexual Some 
college 
Amy 31 White Italian/Irish Heterosexual Associates 
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Deanna 31 Multi-racial "American" Heterosexual GED 
Chloe 30 White Irish Heterosexual Some 
college 
Natalie 27 White Italian Heterosexual College 
Lonnie 24 White Greek/"White" Heterosexual Some 
college 
Caitlin 23 White "New York" Heterosexual H.S. 
Diploma 
Tiffany 22 White  Italian/Israeli Heterosexual 11th grade 
Ava 21 White Egyptian/Hungarian Heterosexual Some 
college 
 
Note. N = 14 
 
The participants grew up in neighborhoods all over Staten Island, allowing for a sample 
with geographic variety that captures representation from both North Shore and South Shore 
demographic groups as illustrated in Figure 3 below. Five of the participants had children, and 
one was pregnant at the time of the interview. Three of those with children had custody of their 




Figure 3. Participant Neighborhood of Origin 
As demonstrated in Table 3 below, at the time the interviews were conducted, 
participants were at various stages of their substance misuse trajectories. Several reported being 
abstinent from all substances for several years; others had been abstinent for a shorter period of 
time. Two women reported ongoing opioid misuse; one had stopped using opioids but continued 
to use marijuana on a daily basis. Most participants were involved in either substance misuse 
treatment, twelve-step meetings, harm reduction services or a combination of the above. Two 
participants were not connected to any substance misuse support. All of the participants were 





Participant Substance Misuse Status and Treatment History 
Pseudonym Age Current 
POM Status 
Current Substance Misuse 
Care 
History of Substance Misuse 
Care 
Camilla 34 Not active Outpatient, 12-Step Outpatient, 12-Step 
Felicia 34 Not active Outpatient, suboxone Outpatient, suboxone 
Molly 33 Not active 12-Step 12-Step 
Nadine 33 Not active 12-Step Detox, Rehab, Methadone, 12-
Step 
Jessica 32 Not Active 12-Step Intervention, Detox, Rehab, 12-
Step 
Samantha 32 Active Harm Reduction Detox, rehab, harm reduction 
Amy 32 Not active Residential, outpatient Intervention, rehab, residential, 
outpatient 
Deanna 31 Active None Outpatient 
Chloe 30 Not active Methadone, 12-Step Detox, methadone, 12-Step 
Natalie 27 Not active Outpatient Detox, rehab, suboxone, 
outpatient 
Lonnie 24 Not active Outpatient, 12-Step Detox, rehab, methadone, 
outpatient, 12-Step 
Caitlin 23 Not active Methadone Detox, suboxone, methadone 
Tiffany 22 Not active Methadone, outpatient Methadone, suboxone, 
outpatient 
Ava 21 Not active None Detox, rehab, outpatient 




Over half the sample (8/14) were exposed to prescription opioids via a prescription by a 
medical professional prior to any misuse. Two distinct groups emerged within the sample when 
looking at those who had been prescribed an opioid compared with those who had not. Among 
the nine oldest participants (Group 1), born between 1983 and 1987, all but one were first 
exposed to prescription opioids via their own prescription. The various injuries or illnesses that 
55 
 
generated an opioid prescription from a provider varied from participant to participant--wisdom 
tooth extraction, car accident, tonsillectomy, knee injury, migraines--but all shared a common 
first iatrogenic3 exposure (see Figure 4 below). 
Molly4: So the first time I ever took an opiate pill, I was probably—I was young, 
in high school, but that was due to a surgery when I had my appendix 
removed…that would be the first time I took them. 
Jessica: I dislocated my kneecap and tore my ACL…and that was the summer 
before my senior year in college….I was prescribed Vicodin. 
Felicia: It happened with my first car accident when I was 18 and the doctor 
prescribes me 10 milligrams Percocet. 
The five youngest participants (Group 2), born between 1990 and 1996, were all exposed 
to prescription opioids for the first time outside of a medical professional’s prescription. These 
young women were introduced to POs by friends, peers, family members or significant others. 
Caitlin: Okay, so my friend [Grace], she—well, I thought she was my friend--she 
was like, “Hey do you want to take a blue5?” and I was like, “What’s a blue?” 
She’s like, “Oh, it’s a painkiller and you’ll get fucked up. You’ll feel great.” And 
I was like, “All right, all right, I’ll try it.” 
The age of first prescription opioid misuse varied dramatically between Groups 1 and 2, 
                                                 
3 David Musto describes three categories of iatrogenic addiction: (1) inadvertent—the use of 
addicting substances where the addictive quality have not yet been identified (2) negligent—a 
the prescribing of a known additive substance to meet the desires of a patient when it is not a 
necessity; and (3) intentional—the use of addicting substances in the cases of terminally ill 
patients or medication assisted treatment using an agonist substance (Musto, 1985). 
4 Names used in the study are not the women’s real names, these have been changed to protect 
the identities of the participants. In addition, any other identifying data has been removed. 
5 A “blue” is slang for a 30 mg oxycodone tablet because of its blue color. This pill was also 
referred to as a “Roxie”, an abbreviated version of Roxicodone, the brand name. 
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with Group 1 beginning POM for the first time during young adulthood. Group 2 began, for the 
most part, during mid-adolescence. Mean age of initiation to nonmedical use for Group 1 was 
24.33, with a standard deviation of 2.67. Mean age of initiation for the Group 2 was 16.8 with a 
standard deviation of .98. 
Group 1 participants were more likely to not know the dangers of POM (77%), in 
comparison to Group 2 (22%). This makes sense in terms of the period during which these 
participants began POM, the earlier years of the epidemic. As the epidemic escalated, 
information about these substances and their addictive potential increased among the general 
population and policy changes further reinforced this knowledge. By the time Group 2 entered 
adolescence, more information was available regarding the nature of these substances. 
 






Almost all participants (92%), had engaged in some sort of recreational psychoactive 
substance use prior to POM. Four categories of experience emerged here: No Use, Little Use, 
Moderate Use, and Extensive Use (see Table 4 below). The No Use group was comprised of 
women who had never engaged in any recreational substance use at all prior to POM. The Little 
Use group was categorized by infrequent, experimental use that did not involve large quantities 
of substances consumed on any one occasion. The Moderate Use group displayed more frequent 
use and larger quantities of substances consumed at any one time. The Extensive Use group 
discussed frequent use with a wide range of substances and large quantities consumed. 
Substances discussed included marijuana, benzodiazepines, alcohol, cocaine and crack, MDMA, 
hallucinogenic mushrooms, LSD, methamphetamine, and ketamine. 
Of the entire sample, only one participant identified no substance use whatsoever prior to 
POM placing her in the No Use group: 
Chloe: Until I was 22 and I had the pills, I was never trying—tried anything. You know, 
I never tried pot until I had already been addicted to pain pills, you know? 
In the Little Use group, participants had minimal exposure to psychoactive substance use 
prior to opioids. 
Camilla: I’ve tried ecstasy, cocaine. You know, I’ve never liked anything that 
was like an upper. I definitely didn’t like those things so like I tried once and 
never touched them again… 
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Participants in the Moderate Use category described regular experiences with substances 
prior to POM. Here most of the use occurred in the context of hanging out with friends in the 
woods or partying at clubs, but no habitual use was reported. 
Felicia: …I was in the clubs, I would take a hit of ecstasy or I would do a bag of 
coke, but nothing where I couldn’t put it down and I could party that night and 
then tomorrow not even think about it. 
Those in the Extensive Use group use, discussed prescription opioids as simply another 
substance in an extensive history of substance misuse. 
Nadine: I was a full-blown drug addict at 15 years old, but it was more like 
designer drugs, like ecstasy, K [ketamine],… 
Samantha: I’ve always been an addict…since I’m a little girl, it started with—no 
joke, when I was 14…when I was like 13, 14, I started smoking weed. Then I was 
drinking. Everything I did was excessive…within a year it went from weed to 
alcohol, cocaine, pills, heroin…. 
These women with extensive exposure to other psychoactive substances prior to opioid 
use described significant differences between their relationship to other substances and their 
relationship to opioids. For many, the attraction to opioids was immediate and the use became 
problematic very quickly. Nadine discusses the differences between opioids and other substances 
she had been using regularly. 
Nadine: When I did the opiates that was that euphoric feeling that I was looking 
for, and I think I honestly was searching for that feeling for years. 
More than a third of the sample (6/14) had been exposed to benzodiazepines such as 
Xanax or Valium prior to beginning opioid use, either with or without a prescription. Participants 
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reported benzodiazepines being widely available among their peer groups, and three of these 
participants had been using benzodiazepines without or beyond the parameters of a doctor’s 
prescription. 
Table 4 
Prior Psychoactive Substance Use 
Category Participant Substances Used Prior to POM 
Extensive Use 
Samantha Alcohol, marijuana, MDMA, cocaine 
Nadine Alcohol, Marijuana, MDMA, hallucinogenic 
mushrooms, cocaine, ketamine, 
methamphetamine 
Molly Alcohol, marijuana, MDMA, hallucinogenic 
mushrooms, LSD, benzodiazepines, 
amphetamines 
Moderate Use 
Ava Alcohol, marijuana, cocaine, benzodiazepines 
Tiffany Marijuana, benzodiazepines 
Amy Alcohol, marijuana, crack cocaine, PCP 
Natalie Alcohol, marijuana, MDMA, cocaine 
Little  Use 
Camilla Alcohol, marijuana, MDMA, cocaine 
Felicia MDMA, cocaine, benzodiazepines 
Lonnie benzodiazepines 
Jessica Marijuana, benzodiazepines 
Deanna Alcohol 
Caitlin Marijuana, MDMA, alcohol 
No Use Chloe None 
 
In summary, all participants described either iatrogenic exposure to opioids and/or other 
psychoactive substance use prior to first prescription opioid misuse. There were no participants 
who were entirely substance naïve. All had been primed with a previous experience through their 




You Don’t Feel Pain 
Many participants discussed pain, both emotional and physical pain, as a primary motive 
for POM. For example, Tiffany spent time in foster care during her childhood due to her 
mother’s ongoing substance use. Nadine grew up in a single-parent family with her mother, 
while her father was incarcerated for most of her childhood on drug-related charges. These 
experiences contributed to traumatic and turbulent childhoods and ongoing emotional pain 
during adolescence. 
Several participants discussed histories of sexual trauma: 
Samantha: … A family member, I’m not going to say who, when I was like 7-9, 
10, you know, molested me when I was a---yeah, I was young. 
Nadine: I have a lot of sexual abuse in my story, so that really was a key—I don’t 
know if it made me a drug addict, but it definitely added to it. 
Jessica: My sophomore year of college I was taken advantage of by somebody 
that I considered a really good friend…it happened to be my best friend’s brother.  
For these women, opioid use was related to the emotional pain resulting from the sexual 
trauma they had experienced. 
Samantha: [I]t made you not think about that pain. You know, you kind of just 
felt—like you don’t think about it at all. You just want to be high and fucking be 
in another world so you don’t—you don’t feel pain. 
Amy: It took me out of myself, where like, I guess I didn’t have to feel anything. 
Opioids here are performing the function of pain relievers—albeit in this case emotional 




 For some participants, it seemed as though physical and emotional pain symptoms were 
intertwined and difficult to detangle. Deanna discussed how she initially was attracted to 
painkillers for help with insomnia, but quickly realized that they were helpful for other sources 
of both physical and emotional pain as well. 
Deanna: As the problem progressed, I was like, you know what, this might help 
me with my knees, this might help me with my back, trying to numb the 
emotional thing that I was going through. 
Natalie: I was very athletic so I always had back pain. Then when [my best 
friend] died, I was like crying so much and I remember my back was killing me, 
and I was at her funeral and my friend offered me one and I was like, “I feel 
better.” And I guess I was so depressed and stuff, I was like, “My back feels 
better,” I wasn’t like crying, you now?” So like I took it and I got through the 
funeral. 
Jessica describes a similar experience after tearing her ACL and beginning pain treatment. 
Jessica: It made sitting on the couch a lot more comfortable because I didn’t have 
a lot of mobility….it helped a lot with any emotional pain that was going on in 
my life because it wasn’t only helping with this pain [points to her knee], it was 
helping with this pain [points to her head].   
What’s the Big Thing? 
For a few of these young women, the leading motivation for initiation of POM was a 
sense of curiosity about the substances. Lonnie remembers wondering: “What’s so good about 
these? What’s the big thing?” Lonnie helped her boyfriend sell opioids and she witnessed young 
people her own age spending hundreds of dollars to obtain them. In essence, she was curious 
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about why people were so attracted to these opioids and willing to spend so much money for the 
experience. 
Anxiety and Stress 
For some, the opioid use was largely an answer to anxiety and stress. 
Molly: I had a lot of personal things going on in my life at that time, I had just 
had my daughter, I was married at the time. I’m no longer married, I was married 
at the time, and he found himself in a whole world of trouble with his job. We had 
a lot of stress going on at my household and a friend offered me that and I felt 
better. 
It seems that the stress Molly discusses here is closely related to her feelings of being 
overwhelmed in her roles as mother and partner. 
Ava observed how visible this stress looked like from the perspective of an observer of 
pill purchases at a house where people were buying and selling substances:  
Ava: [G]irls…would be like very frantic and like they needed to get their stuff to 
calm down. And it was like—you know I would see them, like if I was at 
somebody’s house like getting something and like the guys would come in and 
they’d be all like “Oh, what’s up” whatever. Whereas the girls would come in like 
“Oh, my kids” and this and that, or, “My husband,” “Oh my God, my boyfriend,” 
And then like I just—and then as soon as they’d do it then they’re, good, you 
know? 
There’s Gotta Be Some Part of It That’s Genetic 
Participants reported extensive histories of substance use in their families of origin. 
Almost three-quarters (10/14) of the sample had at least one parent with a history of substance 
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use, while a little more than a quarter (4/14) reported that both parents struggled with substances. 
The quarter (4/14) who reported no parental substance use at all had close biological relatives 
who had substance use histories (see Table 5). 
 
Table 5 
Family Substance Use History 
Pseudonym Mother Father Siblings Other Family Members 
Felicia 
 





IV Substance Use 
 
Alcohol 
Chloe Prescription opioids 
  
Alcohol 
Nadine Pills Heroin 
 
Heroin/alcohol 

































   
Pills/alcohol 
 
Despite an apparently strong genetic influence in the sample, only two participants 
discussed the role of genetic predisposition in their own substance use histories. Jessica made the 
strongest statement about genes, clearly stating a direct link between her family history of 
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addiction and her own POM: ”My mother’s father was an alcoholic. So I know the gene comes 
from that side.” 
Chloe also mentioned genetics and shared her thoughts about nature versus nurture and to 
what extent her own family history contributed to her own story. 
Chloe: My aunt’s an alcoholic, my grandfather was an alcoholic, my great 
grandmother and great grandfather were alcoholics. You know, it was always 
alcoholism. It’s just in me and my mom it manifested in a different 
substance….there’s got to be some part of it that’s genetic because, you know, 
anyone can become an addict, but I think your chances are greater if you had 
parents that were or grandparents. 
The majority of participants made no mention of genetic predisposition as a contributing factor 
in their own POM trajectories. 
In summary, individual-level factors discussed by participants included the entire 
sample’s exposure to both prescription opioids and/or a wide-range of other psychoactive 
substances prior to POM. In addition, histories of both emotional and physical pain were 
endorsed by many in the sample. Mental health histories, particularly anxiety, were common as 
was a genetic predisposition for addiction given family history. Taken together, these individual 
factors combined to create heightened risk at the individual level for this group. 
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CHAPTER V: INTERPERSONAL AND COMMUNITY CONTEXTS 
 
 This chapter presents findings at the interpersonal and community levels. These contexts 
are not distinct from the individual level factors noted in Chapter 4. Factors at each of these three 
levels are continuously interacting and reinforcing one another. At the interpersonal and 
community levels, findings in the context of family, friends, intimate relationships, doctors and 
Staten Island are presented. 
Focused Codes 
It Starts at Home First 
The first major finding at the interpersonal level involves the significant environmental 
exposure to substance use that most of the participants experienced in their families’ of origin. 
The majority of the participants were exposed to the substance misuse of one or both parents as 
they were growing up. Almost three quarters (10/14) had at least one parent who struggled with 
substances. A little over a quarter of the sample (4/14) reported that both parents struggled with 
substances; the same amount (4/14) reported no parental substance misuse at all (see Table 5). 
Many discussed the nature of this exposure and its impact. Amy summarizes the theme 
well: “I do think it starts at home first.” Tiffany describes the pervasiveness of substance use in 
her home and how this became the entry point for her own use: “just basically living in a house 
where drugs were everywhere it was hard not, you know, to not do it, so I fell into it.” The 
presence of substance use in some homes created powerful norms around its use.  
In some cases, parents were involved in treatment and recovery programs and 
participants shared these experience with their parents. This exposure served to expose and 
normalize addiction treatment and recovery. Caitlin remembers accompanying her father to his 
methadone clinic when she was five. Molly talked about a culture of recovery being embedded in 
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her family life. She was able to observe her father, through his 12-Step participation, help many 
others achieve their goals through sponsorship. She remembers going to his sober anniversaries 
and felt a sense of pride about all that he had accomplished. Here we see a relational component 
at work---substance use recovery and treatment facilitated connection to a parent.   
In some cases, parents struggled with substance use their entire lives. Amy discussed 
what it was like to grow up in her family: “my father growing up was an alcoholic…I remember 
him going to rehab, I remember him going to meetings. But it was—it’s hard. It’s not easy to 
stop.” 
In some cases, participants were exposed to a parents’ substance use and chose to avoid a 
parent’s primary substance in an effort to avoid problem use in their own life. This avoidance, 
however, did not extend to other categories of substances which in some cases led to substance 
misuse, albeit of a different substance. 
Amy: Seeing my father be an alcoholic my whole life, I didn’t like alcohol 
because I didn’t like how he turned and so I was never really a drinker. But then 
when drugs were around me it’s like, oh, well, this isn’t drinking, it’s different. 
Molly: As a 19, 20-year-old, I knew if a crowd of people, if they were doing 
cocaine, I would never go near because that was my mother’s drug of choice 
when I was a child, so I would say, ‘Oh, no, no, no. look what it did to me, look 
what it did to my family’…I really thought I was going to be able to control it 
because I had so much knowledge from my parents and, like I knew better…I was 
going to be able to drink safely and use drugs safely. I’m going to learn, you 
know, shame on them. 
For both Amy and Molly, exposure to a parent’s substance use became a protective factor 
67 
 
for that particular substance, but did not translate into a protective factor for all substances. 
These women understood addiction to be defined by a problematic relationship with one 
particular substance as opposed to a problem that might extend to other substances as well. 
Being Tired of the Rules 
Some participants discussed specific parenting styles that they felt had influenced their 
substance use trajectories. Amy responded to an overprotective parenting style with rebellious 
behavior in adolescence: 
Amy: They [Amy’s parents] like sheltered me big time. So it’s like as I hit a 
teenage whatever, it’s like I rebelled…they never like—my mom had the sex talk 
with me at like 20-years-old. Meanwhile, I had sex at like 15, 16. You know, I felt 
like she looked at me more innocent than I was. 
This overprotectiveness could have been a function of gender in this case—parents attempting to 
protect a female adolescent in ways that they may not have done for a male adolescent. 
Ava describes her father as “an overbearing, extremely strict and sometimes—well a lot 
of times—very unkind father.” She defines one of her motivations for use as an act of rebellion 
against what she perceived as an overly-controlling parent. 
Ava: My dad was very strict on me, extremely strict on me as a kid…which was 
why I was trying to push boundaries when he wasn’t looking…it was like a 
retaliation against his reins…If you’ve grown up and you were raised by that, 
you’re going to feel some sort of entrapment, like you’re not experiencing life as 
you should…and you start to do things that sort of break the rules, because you’re 





Despite experiences in their families’ of origin, participants resisted blaming parents for 
their own POM experiences. There seemed to be a fine line between explaining childhood 
circumstances and blaming their parents for their own prescription opioid misuse. Participants 
made a point of taking full responsibility for their own situations. Both Tiffany and Amy discuss 
the impact of their parents’ use on their own behavior while making sure not to assign blame to 
them. 
Tiffany: Just basically I think you’re more prone—I don’t mean prone but you’re 
more likely to use when you were raised using…I hate to say that but I feel like I 
use because of my mother. And I don’t blame anybody, I blame me, but, you 
know, I couldn’t get out of that situation, I was young, you know. 
Amy: I’m not saying my mom did a bad job. She did an amazing job, but— 
We Didn’t Know 
Many of the participants reported having had no exposure to information about the 
addictive potential of these substances prior to use, particularly the older group of participants 
(Group 1). Over half of the sample (57%) reported no understanding of what a prescription 
opioid was prior to use.  
Natalie: Like we didn’t know, you know? Or at least I didn’t know. I had no idea. 
And I know the kids that like messed around in high school, they didn’t know 
either. They had no idea. They were just like, “These make me feel good,” but so 
does like skipping class or smoking a joint, so does the occasional ecstasy or 
cocaine. But like nobody knew.  
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Nadine: I didn’t understand when I picked up oxies6 that it was synthetic 
heroin…like, a pharmaceutical company makes this and it’s basically heroin in a 
pill. 
Camilla believed that this information would have made a difference and altered her willingness 
to use large amounts of opioids for extensive periods of time. She suffered for ten years with 
severe migraines that began when she was 17. She tried many types of treatments and saw 
multiple doctors before being referred to a pain management specialist at 27 who prescribed 
opioids. Two years later she was in a car accident where she sustained serious injuries including 
herniated disks in her spine, a broken nose and hand, and several broken teeth. After the accident 
she was placed on a higher dose of opioids and stated that “within 30 days I was addicted.” She 
articulated very clearly that the absence of information about the risks of prolonged opioid 
consumption was significant in her decision to take the opioids. She explained that had she been 
exposed to more information, she might have made a different decision. 
Camilla: So I assumed it was okay. And I feel like if they would have told me—
anyone, doctor, pharma—anyone would have told me how addictive they are, I 
would’ve thought twice about, “Oh, you know, it’s temporary, I’m in legit pain, I 
have all these injuries, it’s okay for me to take them.”  Had I known the 
information then, I probably would have gone in a different direction.   
Interviewer: Nobody shared any information with you at all? 
Camilla: No. Nothing. Nothing as far as how addictive it was. 
Drugs vs. Pills 
One piece of information that was known, and that had an impact on use, was the fact 
                                                 
6 “Oxies” is slang for OxyContin. 
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that prescription opioids were prescribed by doctors. This fact lent these substances legitimacy 
and removed possible concerns about risk that might be associated with “drugs” that came from 
the black market. Even when the pills were diverted and not directly prescribed to the 
participant, the fact that they were originally prescribed by a medical professional for a medical 
condition carried with them the message that they were safe. Several participants mentioned the 
absence of concern as a result of this. 
Chloe: [A]nd here I’m like, ‘oh, it came from a doctor, it’s fine, you know, no big 
deal’. 
Amy: [Y] ou look at it like well, the doctor’s giving it to us so it should be okay. 
You didn’t think you would get hooked on it.  
Prescription opioids were approved by the government, manufactured in labs, advertised 
on TV, prescribed by doctors and distributed in pharmacies. Messaging that these substances 
were safe to take was carried by doctors, pharmacists, friends and parents. Relationships with 
these messengers lent legitimacy to their use, providing a sense of false safety and protection. 
 Messaging about the differences between classes of substances, particularly between 
illicit and licit substances were very prevalent. Chloe discussed prevention initiatives at school 
such as D.A.R.E. that presented no information about the risks of prescription substance misuse. 
Chloe: Never did they mention pills. Pain pills, benzos, Adderall, things like that, 
anything prescribed by a doctor, they never mentioned. 
Amy: I remember heroin was talked about, that heroin is bad, you can’t do heroin.  
But I never realized a pill was a form of heroin.  I never realized that…And a lot 
of my friends thought the same thing  
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Ironically, one of the few places that substance-use information was being addressed overtly, 
school-based prevention initiatives, failed to provide accurate information to teenagers making 
decisions about substance use. 
In families where substance use was prevalent, opportunities to educate were also absent. 
Molly talked about how there was little discussion in her own family about substances, despite 
her mother’s own active substance misuse. In some families, messaging about substances 
mirrored larger societal norms, particularly in the area of illegal versus legal use. Amy‘s mother 
repeatedly told her “don’t do drugs.” When her mother found out that Amy was using marijuana 
in high school, she sent her to therapy “because she was so scared.” Amy’s mother was clearly 
concerned about the risks involved in adolescent marijuana use. In terms of legal substances, 
however, the messaging was different: 
Amy: I actually have TMJ and my mom would give me a piece of the pill, of my 
dad’s pills, if it was really bad and when I would take it, I would get a little 
buzz… 
Here we see a clear distinction between messaging about licit versus illicit substances from 
parents, where one was feared and the other condoned. 
Show Me Who Your Friends Are 
Another motivation for first POM was peer culture and wanting to connect socially with 
other peers. The desire to connect and a be a part of a peer group is a strong motivator during 
adolescence in particular. Amy describes it this way: 
 Amy:…hanging out with my friends, like seeing them do it made me want to do 
it…and that’s a big thing, like who your friends are. My mother would always say 
that to me: “Show me who your friends are and I’ll show you who you are.” And I 
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used to look at her like “What the hell does that mean?” But now as an adult, I see 
that because it’s true. Like kids follow other kids. 
 Amy clearly describes that the impetus was hers. Here, the role of peers was closer to 
modeling and norm setting than active peer pressure as it is traditionally understood. In fact only 
one participant, Jessica, mentioned being actively pressured or convinced to use a substance, and 
this was in the case of marijuana, not prescription opioids. 
Ava tells the story of a “horrible influence” friend that she was very connected to at this 
time. 
Ava: My friend at that time, she was a horrible influence…we went to Brooklyn 
and we always did, you know, hood rat stuff in Brooklyn…you know, you find 
the drugs, you find alcohol, and you find boys and you just have fun. You go in a 
park, or someone’s apartment that you don’t know…. 
For many participants, peer norms in their social circles provided a backdrop that 
facilitated and normalized these experience and in some cases supported and enabled ongoing 
early use. 
Jessica: It’s not like I had many friends, some of them I was related to, some of 
them our brothers and sisters were the same age, and they knew each other too, so 
our families knew each other. But they were all doing the same thing [Drugs]. 
 Some participants noted that spending time as a younger adolescent with older 
adolescents or young adults became a conduit for substance use. 
Lonnie: The only reason I think I did Xanax is because my older brother and his 
friends did it and I thought it was the cool thing to do. 
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Nadine: I hung out with older girls from ______ High School…they were all like 
two, three years older than me. 
Molly: We just hung out, and there was always a crowd of older people with 
things that I shouldn’t have been doing.  
I Wanted to Be His Girl 
Lonnie’s first experience with opioids was in high school. She was selling opioids and 
benzodiazepines at her high school for her boyfriend who had already graduated. She discussed 
being attracted to the particular lifestyle provided by drug dealing and access to money, as 
opposed to being attracted to the substances themselves. Lonnie talks about it this way: 
Lonnie: I guess I was attracted, like, him having like all these nice things, 
motorcycles, and you know, just the lifestyle of it that I wanted, you know, to be 
like his girl. 
The substance use followed the lifestyle choice, not the other way around. Substances came as 
part of the package that included a boyfriend, a motorcycle, and plenty of disposable income.  
The Island 
At the community level, participants expressed thoughts about how growing up on Staten 
Island contributed to their substance use trajectories. Two key ideas to emerge here were 
boredom and unsupervised time. 
Several participants felt that kids on Staten Island were bored.  
Molly: There’s just not really much around here to do for teenagers but find 
themselves trouble. Besides a bowling alley or a movie theater, there’s not really 
much on Staten Island, you know, if they’re trying to intrigue someone that’s 17 
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or 18…I know for me, once I got into high school, I wasn’t really in that many 
extra-curricular activities like I have my kids in now. 
Samantha: There’s nothing to do for these children…what’s really, on the Island, 
what is there to do? 
 Many areas of Staten Island are distinctly suburban, particularly in the South Shore. 
Some talked about how growing up in a place where there was little to attract teenagers, coupled 
with plenty of access to unsupervised areas such as the woods or the beach, created many 
opportunities for substance experimentation for adolescents. 
Molly: My boyfriend, he says, “I don’t understand, everybody from Staten Island 
says that they always drank in the woods. Like why didn’t you go places?” I said, 
“I don’t know, that’s just what the thing was to do.” 
Natalie: Growing up, I was like four houses from a park and like we would all 
used to hang out in the park and drink and smoke weed and do this and that…like 
we started off on the weekends, then it went into like, “oh, it’s a Thursday, close 
to Friday”. 
Pills Were All Over 
Another community-level finding involved easy access to opioids. This was mentioned 
repeatedly as a major element impacting POM trajectories. 
Natalie: [The pills] were all over the neighborhood. Like I didn’t even need a car. 
I was able to walk in any direction and get them…No issues with supply. And like 
years ago, like everybody was on them. Like the whole neighborhood. 
Camilla: I was a “good girl”, you know? And yet it was so easy for me to find 
pills on the street…One day, I saw my neighbor sitting outside and—it seemed 
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like he was doing some shady business [laughs]. Which he was…And so I just 
went up the street and asked him….And he was like “Yeah, I can get that for 
you.” And from then on, my dealer was across the street from me. 
Felicia: Everybody around me always had some kind of prescription of 
something. It was like “Hey, did you know this, you want to try that?” Or, “Yours 
are 10 mg, mine are 30, you want to try it?”...It was like a ring of, you know, 
sharing and giving and trying and selling. 
White Picket Fences 
Several participants observed that families on the South Shore, in particular, lacked 
awareness of prescription opioid problems occurring in their own neighborhoods. Here “South 
Shore” seems to be a proxy for describing a particular combination of race and class experience, 
characterized largely by White families with middle and upper-middle class status, and in many 
cases, of Italian-American origin.  
Natalie: [On the South Shore] they don’t even realize how many people on their 
block alone are using…they think they live in the South Shore—like that’s where 
it is. Like that’s where it is….I really never had to—especially with pills, I never 
had to go far. It was all in the South Shore. 
Natalie seems to be suggesting that embedded in the South Shore’s attitude towards 
addiction were the underlying racist conceptualizations of addiction as being a problem of people 
of color living in other neighborhoods, not their own. Amy goes further to push back against 
stereotypical portrayals about who is an addict and who is not:   
Amy: That’s why it’s so weird when the epidemic happens of pills and heroin that 
you really do see like it doesn’t—it does not discriminate because you can’t say 
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it’s low class, you can’t say it’s only blacks, you can’t—you can’t say that 
because there’s people that have careers. I know when I worked in the hospital, 
there were nurses that were 40 something years old that were mother of three and 
they had an addiction problem because it all started with pills. 
In her statement Amy begins to challenge racist and classist misperceptions about addiction and 
clearly sees that substance use has affected many members of the Staten Island community, 
regardless of race, class or neighborhood. 
Some participants suggested that financial resources served to heighten the risks among 
those who came from wealthier backgrounds. 
Caitlin: I think people here have money… that daddy and mommy’s bank 
account—they use their mommy and daddy’s money. 
Jessica: The pills are very high on the South Shore where the money is. 
Class and race intersect here, particularly in conversations about the South Shore. 
Participants pointed out the seeming incongruity between perceptions of substance use and 
substance users and the communities where many of these substance users were initiating and 
struggling with ongoing prescription opioid misuse. 
Several participants pointed out how the inability to accept the presence of substance use 
in their communities led to a great deal of shame and general silence around the issue. Some 
members linked this to a particular cultural experience of growing up in Italian-American 
families. Jessica suggested that in families of Italian-origin, there was a reluctance to 
acknowledge substance use in their children. 
Jessica: [I]t’s like a Little Italy, Italian, you now, culture down here for the most 
part in the South Shore…the traditions that is wrapped up into Italian families is, 
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you know, the almost like the white picket fence theory where everything looks 
amazing on the outside but there could be a lot wrong on the inside and don’t tell 
anybody about it but sweep it under the rug and make sure everyone knows how 
good you are doing. And I think a lot of that has to do with the fact that, as much 
as we don’t deal with what’s going on inside our houses is to kind of have to put 
on this fakeness or this face to appease, you know, so our parents look good in the 
eyes of their cousins, you know? 
Molly, another participant who identified as Italian-American, discussed this same stigma around 
substance use. 
Molly: Everybody I know here, on Staten Island, no one wants to talk about 
anything. Everybody is so embarrassed of everything…it’s like everything is hush 
hush. 
In summary, interpersonal and community level factors all played a role in POM 
initiation among this group of young women. Elements such as parental substance use and 
parenting style; lack of information about the risk of addiction associated with prescription 
opioid use; the message that opioids were safe being delivered by relationships with friends, 
family and providers; the desire for social connection to peers and intimate partners; the 
immediate availability of prescription opioids in Staten Island during the time period under 
consideration; and the stigma and shame in regards to substance use embedded in Staten Island 





CHAPTER VI: PRESCRIPTION OPIOID MISUSE TRAJECTORY 
This chapter introduces the trajectory of prescription opioid misuse from initiation of 
misuse to maintenance of an opioid use disorder: First POM Event, Early POM, Problem 
Recognition, and Maintenance. The trajectory includes participants’ descriptions of the source of 
the opioids for the first misuse event and what this event was like. It then goes on to present 
description of the early days of prescription opioid misuse, the moment at which the experience 
became defined as a problem and what led to that realization. Also considered is how and why 
problematic use was maintained over time and how, in some cases, prescription opioid misuse 
transitioned to heroin. 
Focused Codes 
My First Time 
Prescription opioids used in the First POM Event came from participants’ own 
prescriptions, peers, significant others and theft. For about a third of the participants (5/14), an 
opioid prescription of one’s own was the direct conduit to first time misuse. In Chloe’s case, 
leftover pills from a previous surgery provided the pills that were misused at the First POM 
Event. 
Chloe: I had surgery like a month or two beforehand, and I was having some 
anxiety, so I took one of the Percocet. And I had never taken it a way before 
without it being for pain relief. And even though I was having pain, it probably 
wasn’t enough where I needed to take it, you know. But something just possessed 
me to take it. 
Friends, peers and siblings were significant sources of prescription opioids in many 
initiation experiences. About a third of the sample (5/14) received the prescription opioid for this 
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event directly from a friend or peer. In these cases, peers provided the direct introduction to the 
first experience. In some of these cases, friends introduced participants to pill use within the 
context of relationship support. Natalie talks about a friend offering her an opioid at a funeral to 
help her cope with her distress. In this case, Natalie describes no coercion, ill will or profit-
making motive. Her friend obtained them from his father who had cancer and “would just like 
mess around with it.” Natalie understood his offer of the pill in the context of his desire to be 
helpful and supportive. As was seen earlier in “We Didn’t Know,” these friends often didn’t 
understand the potential risk of an introduction to prescription opioids and where this could lead. 
In other cases, peer-to-peer introductions took place as part of pill trades or sales. This 
group describes their introduction to POM within the context of peers who were involved with 
pill-selling or trading and seemed to be operating from a profit-motive or in order to support their 
own use. Ava obtained her first oxycodone pills through a pill trade. She was in Brooklyn and 
she had several of her own Adderall pills with her. On this occasion, Ava met a friend who sold 
oxycodone pills. When he found out that Ava had Adderall, he suggested a pill trade. 
Ava: So it was like, you know what? Okay, I’ve never taken oxycodone before. 
That’s what he had. And so we did a trade. He gave me two, I gave him 
two…which on the street is a very good deal [laughter].  
Deanna discusses how an acquaintance gave her painkillers because Deanna was having 
trouble sleeping. After several occasions when her acquaintance provided these for free, the 
terms of the arrangement shifted. “After about three or four days…it was like, “would you like to 
buy them?” Deanna later came to understand that this woman was in the pill-selling business and 
that she was motivated by the profit she could make from these sales. This situation differed 
from other situations discussed above where the introduction was understood to be in the context 
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of a supportive friend as opposed to a peer that might have had a profit-making motive. 
Only two of the participants first used in the context of a heterosexual relationship. Both 
of these women were asked whether they felt pressured into the initiation, and both denied any 
coercion.  
Lonnie: It was my own decision, you know. I just—it was like a terrible 
decision…once I went into the lifestyle… 
Nadine: No. I was always the one to initiate things. 
Two of the participants stole prescription opioids from their parents that they used for 
their first use event. Here we see evidence of access via prescription opioids in the home, and the 
dangers presented due to widespread availability during this era (see Chapter 2). 
Oh Wow, I Like These 
  Every participant was asked the question: “Can you tell me about the first time you used 
prescription painkillers where you recognized that you had an experience other than pain relief?” 
The majority (71%) of participants identified their “first time” using prescription opioids in a 
nonmedical way as a discrete event that they remembered very clearly. 
Chloe: The first time I ever used I was actually, I was at home, and you know, I 
just remember feeling really good, like you know, I got, I got giggly and I got 
happy…it kind of just had such a great feeling. Like you just felt so good and like 
I didn’t have any anxiety, I didn’t have any worries. I was just able to have fun. 
And my father had just passed away and it was like I didn’t feel any pain from 
that and it was just like everything just felt better.  
Ava: And so I took it that night. And I just felt like—after it had kicked in, I 
smoked weed to like make it kick in, and it’s just like, I immediately—I knew it 
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was working because I felt this warm ball of just like—just rush like through me. 
And it was just like so nice. I like went for a walk that night, around 11:00. It was 
very relaxing. I was like, “Oh wow, I like these.” 
Nadine: I was already doing K7 every day, and I was just, like, I don’t know, I 
was just, like, an emotional mess with my dad, and I guess, like, it wasn’t working 
anymore, the K, for me. And I took a half, and then [snaps fingers] that was it. 
For this group, the First POM Event was described as immediate and unmistakably 
appealing. Associated with the memory of this first event was the identification of an immediate 
attraction to the experience—an experience of relaxation, a sense of well-being, a euphoric 
feeling, reduction of anxiety and depression, reduced pain, and increased ability to sleep. 
The two participants who discussed negative symptoms (nausea or vomiting) at a first use 
event described the positive experiences as significantly outweighing the negatives. Lonnie 
describes the combination of positive and negative effects in this way: “[M]y first time…those 
were 10, 30 milligrams. You know what I’m saying? I was throwing my guts up but I still liked 
the feeling, you know?” 
The remaining third of the participants did not remember a singular moment that was 
identified as “the first time.” For those who had previous exposure to opioids via a prescription, 
experiences were described as positive, albeit not as easily identifiable or memorable. Here is 
Amy describing her experience with a prescribed opioid prior to POM. 
Amy: I was probably 18 and I had my wisdom teeth pulled…so they gave me 
Vicodin…. 
                                                 
7 “K” is short for “Special K” a slang term for ketamine, a dissociative anesthetic. 
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Interviewer: Okay.  Did you misuse that at all or was that just take them and 
then—was there any high or any experience of like “Oh, this feels good.” 
Amy: A little bit, yeah….my mother controlled them a lot. But I would sneak 
one or two here and there…I felt a little buzz from it so… 
Camilla discusses three different prescriptions for opioids that she had in her adolescence 
and young adult years, prior to what she identified as her “first time” experience.  
Interviewer: Okay. Do you remember what that—in these three situations, was 
there any kind of experience beyond just pain relief….  
Camilla: …I definitely remember that, when I was taking them, that “I probably 
don’t need to take this dose today because I’m not going anywhere, doing 
anything,” but I took it anyway…and not thinking it was a big deal.  
For these women, opioid prescriptions were associated with pleasurable experiences but not 
necessarily identified as first as a First POM Event.  This point is an important one as it speaks to 
opioid priming scenarios that are not necessarily identified as “The First Time” but experiences 
where opioids are recognized as pleasurable and providing an experience that is not exclusively 
about pain control. 
That’s When I Knew I Had a Problem 
Early POM experiences varied from participant to participant. Some were entirely alone, 
others engaged in POM with peers or family members. Natalie discussed the extent of her shame 
around prescription opioid misuse, and this led to her always using alone, never in the context of 
friends or parties. 
Natalie: I was like embarrassed of it, you know? My—I—my friends were all 
straight people. I mean, yeah, obviously I know people, those people, but those 
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aren’t my friends, you know. Like my friends don’t do drugs. So nobody 
knew. You know, nobody knew. So that was [short pause]—that was rough.  
Other women discussed early POM with family members. 
Tiffany: I used with my mother, I used with my brother, with my sister, so it was 
a family thing now. 
Chloe: Me and my mom were addicts together and so we were just, when we 
would take them, we would just sit and talk and hang out and everything. 
Tiffany and Chloe’s experiences both illustrate a relational component to early use that is 
particularly gendered. In these situations, using with a parent or other family member involves 
connecting to and maintaining relationships within the family unit.  
 For many participants, Early POM escalated very quickly to Problem Recognition. The 
question posed by the interviewer was: “When did you first realize that your use had become 
problematic?” In response, many women discussed this time period in terms of several weeks or 
a month.   
Molly: I was 23 or 24 years old, a friend gave me oxycodone, 30 mg, and then 
within two weeks I was at the doctor’s office asking for them. 
Natalie: It’s crazy how like addicted you can really get like so fast. You know, so 
fast. I—I’m saying like a month or two but really it could have been less than that. 
Chloe: I’d only been using about a month—six weeks. 
There was often a complete lack of knowledge about opioid withdrawal among the 
women which paralleled their lack of knowledge, discussed earlier, of the addictive potential of 
these opioids. Some participants only began to understand that their use had escalated to 
physiological dependency when withdrawal symptoms such as bone, joint and muscle pain, 
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sweating, fever, chills, and gastrointestinal distress emerged. For many participants, these 
symptoms were first interpreted as some other health issue. Understanding that the experience 
was in fact opioid withdrawal usually involved either a peer sharing that information or taking an 
opioid which resolved the withdrawal symptoms. 
Natalie: I didn’t know I was addicted to them because I’ve never been addicted to 
anything before, until like one day I just didn’t take them. I was….going into my 
senior year of high school and I didn’t do one that morning and I was in class and 
I was sweating, everything hurt, and I was like, “What’s going on?” And I was 
real athletic so I had softball that day and I was like “I can’t even move, you 
know?” and then as soon as I left my game, I went and I got them and I felt better. 
Chloe: I was sick and I was like “What is this? What am I going through?” And 
my boyfriend at the time stayed with me and he like looked it up and he was like, 
“You’re going through withdrawal like, from like drugs.” 
Nadine: You know when I realized? When my boyfriend didn’t get his script for 
the first time…I didn’t know what was wrong with me. I was just sweaty and hot 
and, and my stomach was upset, and I just thought I was getting sick…and my 
boy told me. He was like, [Nadine], you’re going through withdrawal.” 
Others discussed behavioral cues, not physical symptoms, that signaled a physiological 
dependence on opioids. For Ava, this behavioral cue involved stealing from family members. 
Ava: That’s when I knew I had a problem, was when I wasn’t specifically looking 
for Percs8 and saving them for a day when I didn’t have anything to do. It started 
                                                 




like progressing into like, uh, stealing or selling my old gold jewelry for cash so I 
can buy drugs. 
Natalie realized that she was spending more and more money on opioids. Her tolerance was 
increasing and she needed larger and larger amounts to achieve the same effect. She describes 
how at the beginning of her use, the pill would last five or six hours. She would take one in the 
morning, and still feel fine in the mid-afternoon. Soon, however, she noticed that she would have 
to take one earlier in the day and then again in the afternoon, in order to maintain the feeling—
“And then it was off to the races really fast—really fast.” 
For some, problem recognition did not occur for several years, during which time 
tolerance increased and use escalated. It wasn’t until their supply of opioids was disrupted that 
use was identified as problematic. 
Lonnie: I was doing them for about two years and my tolerance went from doing 
like two a day to twenty a day where I couldn’t even wake up without them but I 
still didn’t know I had a problem because he [Lonnie’s boyfriend] literally had so 
many. He had like hundreds and hundreds…until we broke up and once we broke 
up, that is when I started to realize I had a problem, you know? 
 Lonnie noticed an increase in tolerance and need for higher doses to achieve the same 
effect, but still didn’t fully appreciate the problem until she and her boyfriend broke up. In this 
case, problem recognition was influenced by disrupted access to opioids that she had become 
habituated to. Regardless of whether this disrupted access occurred after a short or long period of 
time, lack of access led to physical or behavioral changes that in turn led to an acknowledgement 
that use had become problematic. 
 The feeling that the prescription opioid misuse had not solved the original problem and, 
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in the end, had simply served to create an entirely new set of problems was universally 
expressed. 
Felicia: Yeah, so now you’re buying drugs and you’re not getting high and the 
pain is still there and you’re not feeling any better and now you’re broke… 
Tiffany: Yeah, at first it was very strong, you know, I didn’t think about anything 
for that—maybe it was like it lasted two or three hours and I didn’t worry about 
anything, you know? It felt happy...it was like instant gratification, like you just 
take care of your problems but then I started to realize you’ve got to face them, 
you know, you’ve got to wake up from that eventually. 
Once participants had acknowledged that a problem had developed, a range of reactions 
emerged. For some, there were attempts to stop which resulted in dramatic and painful 
withdrawal episodes and then a return to opioids to alleviate these symptoms. For others, 
maintenance set in. As long as a regular supply of opioids could be obtained, participants moved 
into what some described as a “functioning addict” mode. 
It’s Very Quiet 
Many participants discussed how easy it was to conceal their prescription opioid misuse, 
even once it had become problematic. The distinct characteristics of the substance, particularly in 
comparison with alcohol, were very appealing and helped to maintain the secrecy around 
dependence. 
Molly: What I think too with the pills is nobody knows…it’s just---especially for 
women. I think with children too, no one sees you, you’re not drinking…its very 
quiet, it doesn’t smell. And I know for myself, and I even look back at pictures, 
besides my weight loss, I look pretty much fine…no one knew in my family until 
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the very end, until I, you know, really, I went down to 94 pounds. 
 Camilla describes selling pills to support her own dependence and how she used this as a 
selling point.   
Camilla: I needed money for pills. And so she [participant’s cousin] used to 
drink, not—she definitely drank—she drank like a college student, I guess you 
could say, and I started telling her, “I’ve got something even better than that and 
you can go to class and not worry about it, not smell like alcohol, still be feeling 
just as good”… it’s much easier for you to take a pill and kind of hide it. 
For Camilla and other young women, pills and pill use was easily concealed, adding to the 
appeal and allowing young women to use it for longer periods of time without others finding out. 
It Gave Me a lot of Energy 
Several participants discussed how energized they felt when they used opioids and how it 
provided them with the stamina to juggle multiple areas of responsibility including parenting 
young children, work, school, and domestic responsibilities.  
Molly: It relieved stress and, you know, it would have the adverse effect to me. It 
gave me a lot of energy. I have always worked, you know, full time and since I’m 
19-years-old. I’ve always held a full time job….It gave me a lot of energy, I was 
able to, you know, do soccer, do dancing school with her [participant’s daughter], 
come home, cook dinner, work all day…It’s just so much stress today. Most 
moms, all, I mean, all of my girlfriends that are moms, that we all work full-
time….they say the same thing, ‘It gave me so much energy.’ 
 Camilla observes how crushing this pressure can be for women trying to fill many roles 
and meet multiple expectations simultaneously. 
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Camilla: I was still working and still bringing a paycheck home and still cleaning 
the house and cooking the meals and taking care of the dog and doing all of those 
things… 
And I feel like, especially for women, they have taken on this role where they 
have to be supermom, they have to work that 9:00 to 7:00 and raise the perfect 
children and not be, you know, body shamed and—you know, they have to be a 
size 2, they gotta have the perfect kid, they gotta be the CEO and they have to do 
it in Christian Louboutin’s. 
For women trying to manage multiple areas of responsibility, opioids served as 
performance enhancers, allowing them to function at very high levels and meet demands of 
partners, families, jobs and children. Interestingly, stimulants or “uppers” are more commonly 
associated with performance enhancement properties. These experiences of opioids as 
performance enhancers are less commonly discussed than the more common properties of 
relaxation, euphoria and sedation. 
Camilla discusses expectations from her family to care for her elderly grandmother and 
pointed out that these were particularly gendered. She talks about how as a female, she was 
expected to assume primary caretaking responsibility for her grandmother when her grandmother 
became ill, despite the fact that her brother lived nearby. 
Camilla: All of the tasks that I was tackling when my addiction really came to be 
were all things that my brother definitely didn’t help me out with. It wasn’t 
even—it wasn’t even a thought in anyone’s head to, “Let’s ask [name of 
participant’s brother] to help out with this.”…I’m the caretaker. I’m the teacher. 
Yeah. I’m the one that—the nurturer, yeah. 
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 As opioids became a “solution” to the stress and problems associated with busy lives and 
multiple responsibilities, going for treatment to address the problems associated with opioid use 
became nearly impossible. 
Camilla: I was finishing up my Masters…I was working full time—I’ve always 
been working full time and going to school full-time….And then my grandmother 
got very sick…and I was still working and still going to school and caring for her 
in between those hours and not sleeping… and they kept me awake, alert, so I 
thought. And functioning…and I kept pushing it off, saying as soon as we get this 
situated with Gram or as soon as things slow down, I’ll take that next step, I’ll 
take that next step… 
Natalie: Maybe if I wasn’t a functioning addict, maybe I would have stopped 
years ago. But I was functioning….as long as I had them [pills]. If I didn’t have 
them, then I wasn’t holding anything together. I was a mess.  
You Lose So Much Weight 
Several women commented that opioid use contributed to weight loss and this factor was 
appealing for women.  
Caitlin: Women are more self-conscious, like a guy doesn’t care if he’s called fat…and 
you do drugs, you lose so much weight…I was very unhappy with my body and when I 
started doing drugs I lost a lot of weight, I got compliments, “Caitlin, you look great, 
Could I take you out?” 
For Caitlin, the fact that opioids suppressed her appetite and led to weight loss led to increased 
attention from men. Caitlin went on to say that when she began her methadone program, she 
gained all the weight back. While she didn’t acknowledge this as a demotivator for treatment, it’s 
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easy to envision the weight gain associated with stopping substance use as a disincentive to 
continue in treatment for those sensitive to issues related to body image and weight. 
Females Can Run Longer 
Several participants felt that women were able to maintain their opioid habits for longer 
periods of time due to particular gender-specific factors. Both Tiffany and Lonnie talked about 
sex-for-drugs relationships.   
Tiffany: I’ve never sold my body but I’m saying girls would go to that extent. I 
never got to that point. I was never desperate, you know. 
Lonnie: Women stay out there longer because I feel like for women—guys buy 
them their drugs. I feel like girls could easily prostitute themselves for money and 
drugs…females can run longer, you know? 
And some eluded to the fact that in the case of pills, women could ask for them more easily, and 
perhaps with greater success. 
Felicia: The guys are pretty much more embarrassed to go to the doctor and ask for a 
prescription. So like they’ll send their girlfriend to get the prescription. 
Heroin 
Many participants spoke about how easy access to prescription opioids changed 
dramatically between 2010 and 2013. It was during this time period, particularly after iStop, the 
New York state prescription drug monitoring program, was implemented that many of the 
participants turned to heroin (see Figure 4). Nearly 60% (8/14) of participants initiated heroin 
use at some time during their opioid use trajectories. Within this group that transitioned to 
heroin, 88% (7/8) did so after iStop was implemented in 2013 (see Figure 4). Some participants 
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described how prescription opioids became prohibitively expensive and heroin became the only 
realistic option for curbing withdrawal symptoms. 
Amy: Well, when Percocets were so hard—not even Percocets anymore, it was Roxies9, 
the oxycodones…and they were like $10, $15 dollars a pill, they jumped up to $30, $35 
dollars a pill, which is insane, and they were so hard to come by because all the doctors 
now had stopped writing their scripts and people couldn’t get it. So now, I remember my 
friend who I used to get pills from was like “Well, I don’t have pills but I have this.” And 
I didn’t know what it was. He said it was heroin. I said, “No, I can’t do heroin,” and the 
moment you’re sick you really don’t care. And he said, “Oh, you do a little bit, you won’t 
be sick anymore.”  And that’s how it started.  I did a little bit and that was it. 
For others who had less trouble obtaining prescription opioids from medical 
professionals, heroin was simply another substance to try that was readily available in a variety 
of peer contexts. Felicia was introduced to heroin through another parent on her son’s Little 
League baseball team. 
Felicia: Well, with the heroin it was because I met a baseball mom on my son’s 
first season of Little League and I thought I had met a nice girl and I was like oh, 
she could be—her son was my son’s age and we could hang out and be friends 
and I didn’t know that she was an IV user…So one night we were hanging out 
with the boys and she was like, “Are you into heroin?”  And I said, “No.” She’s 
like, “Oh, you want to try it?”  I was like—I said, “I’m not shooting it,” ‘cause I 
was scared of needles. She goes, “No, you can just snort it.” So I thought it was 
                                                 
9 “Roxies” is a slang term for Roxicet, a prescription opioid that contains a combination of 
oxycodone and Tylenol. 
92 
 
something where I could do it once like anything else and just never do it 
again. Little did I know that that first thing sucks you in. So I was introduced to it 
that way. It wasn’t something that because I had no pills I was looking for it.  
Some women suggested that not moving to heroin was not an active decision but simply 
a lack of access. Molly expresses very clearly how lucky she feels that she wasn’t exposed to 
heroin in her social circle, because she would not have had any problem transitioning. 
Molly: I count my blessings all the time that I was never around anyone that was 
injecting heroin, because I wouldn’t have thought twice about doing it. I would 
have did it. That’s just my personality. I mean, it was my personality growing up 
from a very young girl, I just, if it was there, “Sure.”  
This chapter describes the initiation trajectory from First Pom Event to Maintenance. 
Participants discussed what this first POM experience was like and the immediate appeal of this 
powerful substance. Also presented were early POM experiences and when misuse became 
identified as “a problem”. Findings on how and why problematic use was maintained over time 
are also covered, as are the experiences of those who transitioned to heroin. Chapter 7 presents 




CHAPTER VII: DISCUSSION: EMERGENT THEORY 
The purpose of this study was to understand the social processes involved in young adult 
women’s initiation of prescription opioid misuse in Staten Island, New York. Additional 
questions considered were (1) how participants described their initiation experiences; (2) in what 
ways they experienced family, peer and intimate relationship contexts as influencing these 
initiation experiences; and (3) what role, if any, did race, class or ethnicity play in the 
experiences of research participants. Fourteen interviews yielded an abundance of data 
addressing these questions and findings were reviewed extensively in Chapters 4-6. Through an 
iterative analysis of these findings, a grounded theory of the initiation trajectories of these young 
women has emerged that begins to answer these questions. 
Overview 
This theory describes the initiation to prescription opioid misuse of a group of women 
struggling to navigate the demands of adolescence and young adulthood in Staten Island, New 
York between 2000 and 2015. Study participants experienced a variety of risk factors at the 
individual, interpersonal and community levels. Some risk factors seemed related to typical 
developmental challenges such as the desire for peer connection and curiosity about substances. 
Other risk factors involved major traumatic experiences, losses or serious physical injuries that 
were out of the ordinary and which led to unusually high levels of pain and stress. Still other 
risks included genetic predisposition and environmental exposure in families of origin. 
Regardless of the cause, all of the women interviewed had insufficient protective factors to 
facilitate healthy coping and prevent serious opioid disorders from ensuing. 
A combination of elevated individual, interpersonal and community level risks and 
insufficient protective factors created the perfect context for prescription opioid misuse to 
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emerge. Initially introduced through either their own prescriptions or through peers, significant 
others, or family members, these young women found these opioids to be accessible, 
inexpensive, socially sanctioned and (perceived as) risk-free. First encounters with POs were 
powerful and highly effective. Many women experienced instantaneous relief of pain and 
suffering within minutes of taking them for the first time--prescription opioids became a perfect 
solution to the stress and pain in these women’s lives when other solutions were not as available 
or as effective. 
First POM Events were followed by POM experiences that rapidly increased in frequency 
and amount of substance ingested. And while these Early POM experiences helped to address 
immediate needs, regular use soon evolved into physiological dependence and Problem 
Recognition emerged. Problem Recognition resulted in efforts to curb or desist use, with many 
failed attempts and relapses. Many women settled into Maintenance for long periods of time as 
they found that POM continued to meet their needs despite the attendant negative consequences. 
Eventually, however, negative consequences overrode the benefits gained from POM and many 
found help through substance use treatment, self-help groups, pain management programs, 
mental health treatment and medication-assisted addiction treatment. Those who were able to 
stop prescription opioid misuse continued to struggle to meet the demands of their lives while 
parenting young children and/or navigating the pressures of maintaining jobs and relationships. 
Others were not able to curb their use and continued to struggle. All of these young women were 





Individual, Interpersonal and Community Level Factors 
Adolescent and young-adult women interviewed for this study discussed priming 
experiences at the individual, interpersonal and community levels. Individual-level factors 
included exposure to both prescription opioids and/or other psychoactive substances contributing 
to a greater vulnerability for developing POM. In addition, histories of both emotional and 
physical pain were endorsed by many in the sample. Mental health histories, particularly anxiety 
and depression, were common, as was genetic predisposition for addiction given family history 
and ongoing stress from caretaking and breadwinning responsibilities. Taken together, these 
factors combined to create heightened risk at the individual level. 
At the interpersonal level, family members, peers, intimate relationships and medical 
providers made up the bulk of the risk environment. Many parents of the participants had 
histories of substance use, and participants grew up in and around families struggling with 
addiction. Some women responded to parenting styles that were over-protective and sheltering 
resulting in rebellious behavior that included POM. Messages that opioids were safe and non-
addictive were carried through relationships with friends, family members and medical 
providers. Women who would never have tried a substance with similar properties, such as 
heroin, had no understanding that prescription opioids had virtually identical physiological 
impact. Messages about these opioids were transported between people in small, immediate 
networks and validated through the implicit trust in those relationships. This relational 
component of messaging about prescription opioids, accompanied by a lack of information about 
possible risk, supported and enhanced uptake of these substances. 
At the community level, Staten Island itself played a role with its abundance of 
inexpensive and easily accessible prescription opioids. In addition, there seemed to be a lack of 
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activities that were attractive to young people. Abundant idle time provided opportunities for   
adolescents to gather and engage in substance use. Absent from these young lives were enough 
protective factors (e.g., participation in meaningful activities such as art, sports, spiritual 
communities) to offset heightened risk factors. Had these been in place, these women might have 
found other ways to cope with stress and pain. 
Initiation Trajectory 
In terms of the trajectory of this experience, the First POM Event was often relational in 
character involving a family member, a significant other or a friend. Notably, these experiences 
were transformative. They were not only pleasant, but also answered a deep need and end to 
several types of suffering. They brought relaxation, well-being, euphoria, reduction of anxiety 
and stress, elimination of emotional and physical pain, and improved sleep. First POM Events 
quickly escalated to habitual use for these women, as physiological dependence rapidly set in. 
Participants described very short time periods between the First POM Event and Problem 
Recognition stages, discovered largely through experiences of withdrawal. This realization 
generally occurred when access to opioids became restricted and physiological and behavioral 
changes were noted, for example, feeling sick, stealing or spending more time and more money 
in the pursuit of these substances. 
Ongoing prescription opioid misuse was generally maintained for years due to the 
prohibitively painful and disruptive nature of discontinuing use and the ready availability of the 
substance. In addition, prescription opioids provided energy and stamina for managing multiple 
responsibilities of work, school, household and family. Prescription opioid misuse was largely 
invisible, allowing some participants’ misuse to go undetected for years. In some cases, being a 
woman also allowed for easier access to opioids than men, whether through intimate 
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relationships with men or obtaining prescriptions from doctors. A little more than half the sample 
went on to heroin use from prescription opioid misuse. In some cases, this was as a result of 
prescription opioids became too expensive, others because heroin was available and provided a 
powerful high, particularly when injected. 
Although not all pathways were identical, all of the participants shared a key core 
experience that begins with an experience of struggle or pain that in many cases was particularly 
gendered. The use of a powerful psychoactive agent provided a simple and highly effective 
resolution of this pain, albeit temporarily. Ultimately, the realization set in that the solution 
didn’t solve the original problem and left the individual with a new set of problems, most 
significantly, an opioid use disorder and the negative sequelae that followed. Gendered 
components weave their way through this theory, sometimes seen and acknowledged by the 
participants themselves, at other times, so intertwined with identities and relationships that they 
are largely invisible. 
This study adds to the knowledge in this area with a qualitative exploration of these 
initiation pathways, attempting to clarify and shine some light on this understudied area with the 
depth that is available through this form of inquiry. In addition, this study describes initiation 
pathways for prescription opioids in particular, a substance that for many had iatrogenic origins, 
adding an extra layer of complexity that is not found in many other substances 
Conclusion 
This is an emerging theory and additional research is necessary to further develop these 
early ideas, however this grounded theory does provide a first picture of what initiation 
trajectories for young women might involve, while highlighting those factors that are gender-
sensitive. Chapters 8 and 9 present a discussion of some of the overall themes that have emerged 
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from the study, how these expand the extant literature in this area, and implications for social 




CHAPTER VIII: DISCUSSION: ADDITIONAL THEMES 
Some key ideas have emerged from this study that serve to expand the current research 
landscape. This chapter presents six of these ideas: (a) the need for an expanded understanding of 
initiation; (b) the influence of female gender; (c) the lack of evidence-based information on 
addiction in the prevention, treatment and recovery communities; (d) some key characteristics 
particular to prescription opioid misuse; (e) the impact of stigma; and (f) the significance of 
boredom. This chapter explores these themes in greater depth and how earlier research is both 
supported and challenged by these findings. 
Initiation Trajectory 
Many addiction researchers have described risk factors associated with initiation and 
maintenance of substance misuse (Jackson et al., 2008; Nelson et al., 2015; Flory et al., 2004). 
Similar to these earlier models, this study uses ecosystems theory as a general conceptual 
framework to understand factors at the micro, mezzo and macro levels that influenced 
prescription opioid misuse in the sample. In addition, this study describes four stages of the POM 
experience itself: First POM Event, Early POM, Problem Recognition and Maintenance. These 
stages have also been described by others in the field (Scheier & Hansen, 2014). 
One of the ideas to emerge from this study is how the traditional use of the term 
“initiation” obscures the complexity of factors that surround a First POM Event. The term 
“initiation” is conventionally understood to be a distinct moment in time when a psychoactive 
substance is first ingested. It is a commonly used concept and referred to a great deal in the 
addiction literature (Behrens et al., 1999; Hobkirk et al., 2016; Mui et al., 2014; Raveis & 
Kandel, 1987; Roy et al., 2011). Embedded in this definition is the idea that this is a problematic 
action of a single individual ingesting a substance during a single moment in time. As a result, 
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this single moment of time becomes a key area of attention for addressing substance misuse, to 
the exclusion of other potential areas of intervention. 
Policies and programs that focus on this conceptualization of initiation as a distinct 
experience are replete in the world of addiction. One of the most commonly known is the Drug 
Abuse and Resistance Education (DARE) prevention program which costs billions of dollars 
annually and is implemented in over 70% of elementary and middle schools in the US (J. H. 
Brown, 2001). Despite its widespread use, meta analyses of DARE have shown it to be 
ineffective in deterring young people from substance use (West & O’Neal, 2004). DARE is 
focused on the development of REAL skills: Refuse, Explain, Avoid and Leave and aims to 
“help youth stay away from drugs by preparing them to act decisively and responsibly in difficult 
situations” (Education | D.A.R.E. America, n.d.). DARE is a prime example of policy hyper-
focus on the moment of initiation. This focus on initiation ignores the many other individual, 
interpersonal and community factors that also contribute to substance misuse. 
As this study has demonstrated, “initiation” is more accurately understood as an 
“initiation trajectory,” a process which begins before birth and continues well into the Problem 
Recognition and Maintenance stages (see Figure 2). While not unimportant, the actual moment 
of initiation, is just that, one moment. Many other “moments” contribute and influence how the 
problem emerges and how it is reinforced and sustained over time. With an expanded definition, 
come expanded opportunities for intervention. When numerous influences and factors are 
understood to be a part of an initiation trajectory, multiple points of intervention are possible all 
along this trajectory. The concept of “initiation” and how it is defined is thus very important in 
the development of effective practice and policy addressing substance misuse. 
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In the particular scenario of prescription opioid misuse, a distinct “initiation” moment is 
further complicated by the fact that many of the participants had previously been exposed to a 
prescription opioid, albeit in the context of a medical prescription. In an attempt to pin down a 
single moment in time that could be categorized as an initiation event, the question posed to 
participants was: “Can you tell me about the first time you used prescription painkillers where 
you recognized that you had an experience other than pain relief?” While many women were 
able to identify a moment of initiation defined in this way when first questioned, others had a 
harder time doing so. Several women who initially identified an event as “My First Time” went 
on to say that they had experienced pleasurable effects from these prescription opioids on earlier 
occasions when taking them in the context of medical treatment, but only recognized this when 
prompted to do so by the interviewer. This point is extremely important. The priming that came 
with earlier pleasurable experiences with this same substance facilitated and contributed to its 
uptake during the identified First POM Event.  
Influence of Gender 
There are few etiological models for adolescent and young adult substance use that have 
examined risk and protective factors for girls and young women in comparison to boys and 
young men. The models that do exist have generally found that while there are distinct pathways 
for substance misuse in girls, the gender variations are more likely to reflect differences in how 
these factors operate and the strength of their impact, rather than being entirely separate and 
distinct factors altogether. 
This study confirms these findings. As was discussed in the grounded theory in the 
previous chapter, gendered components weave their way through these women’s stories, some 
seemingly more gendered, others less so. As with other etiological models, influencing factors 
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here seemed to be more a matter of degree of impact and interaction between factors. No 
uniquely gendered pathway, entirely distinct and separate from those observed in studies of 
young men, was apparent. 
 One factor where gender differences have been observed in the literature is in regards to 
motives for nonmedical prescription opioid use. McCabe and colleagues (2007) found that male 
college students were more likely than female college students to use prescription opioids for 
experimentation (35.3% vs 24.4%) or to get high (39.4% vs 24.4%). In the McCabe study 
(2007), the number one motive for nonmedical prescription opioid use among women was for 
treatment of pain, with two thirds of the sample attesting to this reason. In a study by Back et al. 
(2011), women were more likely than men to misuse prescription opioids in order to cope with 
interpersonal stress (73%) and in response to a negative emotional state such as regret, remorse, 
shame or anger (55%). Other studies also find that women are more likely to turn to prescription 
opioids in order to address psychological distress and life stressors, as compared with men who 
are more likely to use opioids to cope with social and behavioral problems (McHugh et al., 
2013). Rigg and Ibanez (2010) found that the most common motives endorsed by men who 
misuse prescription opiods are to subsitute for other substances and social pressusre. Women in 
the Rigg and Ibanez (2010) study endorsed pain relief and and inducing sleep and the most 
common motivators. Jamison et al. (2010) found that men with POM were significanty more 
likely than women to have peers with substance use issues than women in their study.  
 The findings from this study support this earlier research on gender differences and 
motivation in regards to prescription opioids. For the most part, engaging in POM for women in 
this study was an answer to a “problem” as opposed to being motivated by curiosity or to 
experience euphoria. Problems that participants shared included emotional and physical pain, 
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anxiety and stress, desire for connection with peers, and rebellion against overprotective 
parenting styles. Prescription opioids proved to be highly effective solutions to these problems. 
Again, this is an important idea that should inform prevention programming. If young women are 
attracted to prescription opioids because they help address problems, the solution is to address 
the problems, not simply remove the substance. Messaging like “Just Say No” to drugs misses 
this point entirely—simply removing the substance does not address the problems that 
substances are so effective at solving.  
 There is a substantial body of knowledge that describes women’s first substance misuse 
occurring in the context of male heterosexual relationships. In some cases these women were 
pressured or coerced, in other cases they were simply introduced to the substances via these 
relationships. This research on substance use initiation has found that men tend to engage in 
substance misuse for the first time with other men and that women also generally initiate with 
men (Ettorre, 1992; Powis et al., 1996; Rosenbaum, 1981; Taylor, 1993).  
 In studies with injection drug users, some have found that women seem to be particularly 
influenced by a sexual partner’s injection risk behavior (Bryant & Treloar, 2007). Women were 
more likely to be introduced to injection by a sexual partner—51% of female heroin users were 
injected by a male sexual partner at a first injection event (Powis et al., 1996). This is compared 
to 90% of male heroin users who were injected by a friend at a first injection event (Powis et al., 
1996). Some have explained these findings by suggesting that women are pressured to participate 
in substance use by men, particularly in the case of a sexual partner (Anglin et al., 1987; Reed, 
1985). Women initiates have been characterized as “passive and immature” (Bury, 1992).  
Others have challenged this view of women substance users as helpless victims, finding 
that, on the contrary, women are actively involved in the decisions to initiate substance use 
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(Maher, 2000; Rosenbaum, 1981; Taylor, 1993). Rather than being helpless and passive, they are 
actually “purposeful participants” (Payne, 2007). Tuchman (2015) interviewed 26 women 
between the ages of 22 and 63 (mean = 43.2) who were injection drug users (IDU). In this small 
qualitative study, Tuchman found that participants were largely influenced to transition to 
injection drug use by other women and more than half of the sample received her first injection 
from a woman in her social network, not a male sexual partner. Women who were able to self-
inject displayed agency around the context of their use, including safety and risk management. 
In a study looking at prescription opioid misuse initiation in particular, Rigg and Murphy 
(2013) identified several “storylines” in their South Florida study of 90 people between the ages 
of 18 and 51 (mean = 31). They found one specifically gendered path to POM initiation which 
they refer to as “A Male Influence” (Rigg & Murphy, 2013). In this pathway, women were 
typically introduced to prescription opioids via close contact with a male who was already using 
these substances. The initiation frequently occurred within a romantic heterosexual relationship. 
Women described these relationships as “tumultuous and rife with dysfunction and drug use” 
(Rigg & Murphy, 2013, p. 969). Women were often adolescents or young adults when they 
began dating these men who introduced them to the novelty and excitement of this lifestyle 
(Rigg & Murphy, 2013).  
Participants in the current study looked much more like the “purposeful participants” 
described by Tuchman (2015) and Payne (2007) than the “passive and immature” women 
described by Bury (1992) in relationships that were “tumultuous and rife with dysfunction and 
drug use” as described by Rigg and Murphy (2013)  The vast majority of women in the study 
(12/14) were first exposed to prescription opioids through their own prescriptions, friends, family 
members, or theft, not a male partner. Only two participants experienced their First POM Event 
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within the context of a heterosexual intimate relationship and both denied any coercion/pressure 
in those experiences. Only one participant seemed to fit the “Male Influence” pathway described 
by Rigg and Murphy (2013). This young woman specifically talked about being attracted to the 
lifestyle that her boyfriend was involved in and was introduced to prescription opioids through 
him. 
One possible hypothesis for why women in this study showed more agency in regards to 
POM initiation involves the mechanics of substance use. Taking a prescription opioid can be as 
simple as swallowing a pill. The threshold for being able to benefit from the prescription opioid 
is low, as there is no need for specialized equipment such as syringes, spoons, pipes, or rolling 
papers. Nor does it require a particular skill set such as learning how to use a cooker, tie a 
tourniquet or inject a syringe. The ease of ingestion might be responsible for allowing women 
more agency over their prescription opioid misuse initiation experiences. Some research supports 
this hypothesis on patterns of POM. Back et al. (2011) found that men were more likely to 
consume prescriptions opioids through crushing or snorting them in comparison to women.  
In addition, we could be witnessing variability between birth cohorts. Keyes et al. (2011) 
have investigated the effect of birth cohort effects on gender and alcohol use. This research 
group has observed a diminishing gender gap among younger cohorts in regards to the 
prevalence of heavy drinking and alcohol use disorders. Some hypothesize that increases in 
drinking among younger cohorts are related to changes in gender roles over the course of the 20th 
and 21st centuries. This time period saw large increases in women entering the workforce and 
accessing higher education (Inglehart & Baker, 2000). These authors hypothesize that cohort 
effects reflect changing social norms and patterns among younger cohorts. While Keyes et al. 
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(2011) studied gender-by-cohort effects for alcohol, it’s possible that these same cohort effects 
are also occurring in prescription opioid misuse prevalence. 
In a study with injection drug users in Kenya (Mburu et al., 2019), the authors found that 
the influence of an intimate partner was not entirely determined by the sexual nature of the 
relationship, but also by the economic inequality of the relationship. The majority of women in 
the Mburu study did not have a stable source of income and were economically dependent on 
their male partners in a society which assigned men the roles of primary earner and decision-
maker. In this study, men paid for and provided the substances, supporting the hypothesis that 
both economic and relationship factors intersect to reinforce gender inequality (Connell, 1987). 
Unlike the Mburu (2019) study, this sample reflects a cohort of young women in a 
context where gender roles are much more fluid. Many of these women were employed full-time 
with their own sources of income. In addition, relationship structures did not reflect traditional 
gendered patterns of men acting as primary decision-makers. These changing gender roles 
seemed to impact the access to prescription opioids by participants and decision-making power 
regarding their uptake. 
Another possible reason for increased agency of women in this study could be explained 
by the observations that PO uptake was legitimized by the family members, peers and providers. 
Messages about these opioids were transported between people in small, intimate networks and 
validated through the implicit trust in these relationships. This relational component of 
messaging about prescription opioids, accompanied by a lack of information about possible risk, 
might also have allowed greater agency on the part of study participants.  
Sales and colleagues (2003) have examined gender differences in risk and protective 
factors in regards to POM initiation. They found that three overall factors (family connectedness, 
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self-control, and school connectedness) explained outcomes for both young men and young 
women. Minor gender differences between women and men showed that family and school 
influences were more important for females whereas peer and neighborhood risk factors were 
more significant for males. Kumpfer et al. (2009) found that family factors such as parent/child 
attachment and supervision had a slightly greater influence on girls than on boys and that 
behavioral self-control and community environment had a greater influence on boys. These 
theoretical models suggest that girls are more influenced by family protective factors than are 
boys. Conversely, girls appear to be slightly less influenced by their school or community 
environment than are boys. 
Evidence-Based Information on Addiction 
There is a great deal of misinformation about substance misuse and addiction in the 
society at large and in the prevention, treatment, and recovery environments. Unsurprisingly, this 
lack of accurate information was also observed among participants in this study. In one example, 
some participants avoided the particular substance that their own parent had struggled with, not 
understanding the increased risk that they themselves had to developing substance use disorders 
across all substances. In addition, few of the participants discussed genetic predisposition (2/14) 
as a contributing factor to their own addiction, despite almost ¾ of the sample (10/14) 
acknowledging substance misuse in their family of origin. Incorporating evidence-based 
understanding of differential risks for developing substance use disorders, including genetic risk, 
should be incorporated as a matter of course into all addiction-related prevention programming. 
Prescription Opioids 
In their study of prescription opioid initiation in New York City, Haracopos and Allen 
(2015), found that prescription opioid initiates could be divided into two groups: medical 
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initiates and recreational initiates. Recreational initiates were introduced to painkillers through 
drug experimentation during adolescence and obtained opioid pills though street sources. Among 
medical initiates, first prescription opioid misuse often occurred at an older age than in the 
recreational group and began with medical treatment for an injury or illness that involved a 
legitimate prescription of an opioid. These users eventually transitioned to POM. This study 
confirmed the existence of an older group of participants (referred to as Group 1 in this study) 
being exposed primarily through their own prescriptions and a younger group (Group 2) being 
exposed primarily through peers. The grounded theory developed here expands and deepens 
these earlier findings by examining gender-sensitive factors within these two groups. 
A key theme that emerged in the study was the idea of creating legitimacy of prescription 
opioids through relationships with friends, family members and medical professionals. As was 
discussed in Chapter 5, the vast majority of participants had little idea of the risks associated 
with these substances. They were legitimized through their presence in medicine cabinets in 
homes and the fact that they originated from prescriptions in medical providers’ offices. Even 
when used outside of a prescription, the fact that these were originally prescribed by a doctor for 
a medical condition legitimized their use and gave participants permission to use them without 
fear of long-term consequences. 
Stigma 
In a recent capstone project conducted by Columbia University students at the School of 
International and Public Affairs (Bauman et al., 2017), a needs assessment on the prescription 
opioid crisis in Staten Island resulted in several interesting findings. Interviews with 61 
stakeholders demonstrated that specific characteristics of Staten Island contributed to the 
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explosion of prescription opioid misuse during the first wave of the epidemic including the over-
prescription of opioids, stigma, mental health comorbidity and boredom. 
Many interviewees mentioned that shame and stigma surrounding opioid use was a 
complicating factor in their families or communities; people fear judgment and 
therefore abstain from seeking help. The stigma impacted not only those addicted to 
opioids, but also their families and friends, who were often unwilling to admit that 
someone close to them was struggling with addiction (Bauman et al., 2017, p. 11) 
These findings echo the results of this study where participants described the close-knit 
nature of their communities exacerbating their reluctance to get support. Health care 
professionals and other stakeholders echoed these findings in informal conversations with the 
researcher during recruitment. Several Staten Island providers who met with the PI discussed 
how socio-economic status served to fuel the prescription opioid epidemic in Staten Island. From 
their perspective, parents from middle-class and upper-middle class families in the South Shore 
didn’t want to admit that their children had problems. When problems did come up, the families 
used their social capital to protect and cover up for their children. Stigma and the fear of being 
judged prevented these parents from accessing the help that their children needed. Some of these 
health care professionals also mentioned the specific North Shore versus South Shore dynamics 
explaining that there was a misconception among residents of the South Shore that all of the 
Island’s problems resided in the North Shore. In fact, the opioid problems were worse in the 
wealthier neighborhoods of the South Shore. One treatment professional observed that these 
North Shore/South Shore dynamics were profound and pervasive. 
There is a growing body of research on stigma among those who have relationships with 
individuals struggling with substance misuse. Erving Goffman (1963) referred to this form of 
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stigma as courtesy stigma which he defined as prejudice or discrimination based on one’s 
relationship to someone who has a stigmatized mental health disorder. Corrigan et al. (2006) 
refer to the particular form of courtesy stigma experienced by family members (as opposed to 
treatment providers, friends, coworkers, etc.) as family stigma. Family members of individuals 
with mental health and substance use disorders report experiencing a significant amount of 
family stigma (Corrigan et al., 2006; McCann & Lubman, 2018). These families feel blamed, 
shamed and contaminated (Corrigan et al., 2006) which can impede the likelihood that they will 
reach out for help on behalf of their family member (S. A. Brown, 2011).  
  Many participants in this study identified family stigma and attributed it to a particular 
set of cultural characteristics present in middle and upper-middle class Italian-American families 
in Staten Island who live in the South Shore. While the pervasiveness of family stigma was 
certainly evident in this sample, family stigma is not unique to this particular racial/ethnic/class 
group. Family stigma in regards to those misusing substances has been documented in families 
of all races, ethnicities and classes. There is not a great deal of research on how family stigma 
varies by ethnic, racial and class groups (Corrigan & Miller, 2004), but this is an important topic 
that deserves attention. More research is needed to understand how this type of stigma unique to 
family members might be experienced differently by families of various race, ethnicities and 
classes.  
Boredom 
Another finding from the Baumen et al. report (2017) was related to boredom. 
Interviewees in the needs assessment disagreed about whether or not boredom contributed to 
POM in adolescence and young adulthood. Some felt that a lack of recreational activities led to a 
void and substance use filled that void. They postulated that the mid-teens were a key transition 
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period: “many youth engage in activities with local nonprofits until they reach their mid-
teens…at that point, they either go into varsity sports or do nothing.” Others dismissed the 
boredom theory, claiming it was just an excuse given for substance misuse. These stakeholders 
felt that organized activities would not make a difference, as they were not perceived as “cool” 
by teenagers. 
The relationship between boredom and substance use is an interesting one, particularly 
when the boredom is understood to be signaling an absence of meaning in someone’s life 
(Ember, 2021). Westgate proposes that boredom is “a way that our body and mind are alerting us 
that something is wrong” (Ember, 2021). In this study, boredom as a contributing factor for 
substance misuse was mentioned by many of the participants. Although some did talk about 
sports participation, positive drug tests precluded participation in sports teams for at least one 
participant. Ironically, an activity that could have acted as a protective factor was specifically out 
of reach due to a positive drug test. Several of the women who had achieved stable recovery 
discussed their actions to help others as particularly important elements of their recovery 
journeys. They had found meaning and purpose in helping others who were struggling and this 
provided them with a sense of purpose and meaning that was significant and important. 
Conclusion 
Key themes discussed in this chapter include the importance of an initiation trajectory as 
a concept replacing initiation; when, where and how much the impact of gender is observed in 
this study; the absence of evidence-based information about addiction across the prevention, 
treatment, and recovery landscape; key differences between POM and other substance misuse 
trajectories; the contribution of stigma as a barrier to accessing support; and rethinking the 
connections between boredom, lack of meaning and substance misuse outcomes. This chapter 
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explores these themes in greater depth and how earlier research is both supported and challenged 
by these findings. The next and final chapter presents implications of this research and suggests 





CHAPTER IX: IMPLICATIONS 
This study has highlighted findings that point to several key areas of intervention at the 
individual, interpersonal and community levels. This chapter presents the implications for social 
work practice, policy and research efforts at each of these levels. At the end of the chapter, 
limitations of the study are explored and concluding thoughts are shared. 
Implications: Individual 
Understanding the concept of initiation as a trajectory instead of a single event in time 
has significant implication and demands an expanded range of interventions. Prevention 
programming needs to widen its focus to include the entire context in which prescription opioid 
misuse develops and unfolds. As one of the primary influences on children and adolescents as 
they grow and develop, schools play an important role in supporting the emotional health and 
well-being of students. Schools should not only provide academic programming but also support 
youth when they are struggling with emotional pain, anxiety, stress, conflict with parents and 
developmental challenges. This involves not only hiring social workers or counselors whose 
primary focus is mental health support as an adjunct to educational programming but also 
integrating socio-emotional well-being into the educational curriculum itself. Social Emotional 
Learning (SEL) is a model that has been incorporated into educational environments and has 
shown a great deal of promise for reducing depression and stress, in addition to other positive 
outcomes (Durlak et al., 2011). SEL focuses on helping students develop self-awareness, self-
management, social awareness, relationship skills and responsible decision-making. It is 
integrated into academic subjects and is woven into the overall culture of the school. 
Other school-based prevention programs focus more directly on substance misuse 
outcomes. Core components of evidence-based programs include those that are designed to 
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strengthen bonds to family, school and community and those that teach skills rather than just 
educate about the dangers of substances. The most effective programs spend very little time on 
the actual effects of substances or consequences of use (Kumpfer, 2014). Instead, they provide 
education and skills training that reduce risk factors and improve protective factors that lead to 
improved psychosocial resilience (Kumpfer, 2014). Model programs such as Life Skills Training, 
Project Towards No Drug Abuse, and Brief Alcohol Screening and Intervention for College 
Students have all demonstrated reductions in substance misuse following participation (Griffin & 
Botvin, 2010). 
Implications: Interpersonal 
In addition to the individual-level interventions discussed above, family-based prevention 
efforts can also have an impact on substance use outcomes. Longitudinal studies demonstrate 
that family-based prevention programs, where the family unit is the focus, are some of the most 
effective prevention interventions available (D. R. Foxcroft et al., 2003; David R. Foxcroft & 
Tsertsvadze, 2011). Three family protective factors that seem to be critical in mediators of youth 
outcomes are (1) teaching parenting and family relationship skills and behaviors that increase 
parent/child attachment and love; (2) effective monitoring and discipline skills; and (3) effective 
communication (Kumpfer, 2014). Family Matters, Creating Lasting Family Connections and 
Brief Strategic Family Therapy are all programs designed for families where young people are 
showing early signs of substance misuse (Griffin & Botvin, 2010). All three of these programs 
demonstrated improved outcomes in reduction of substance misuse among participants. 
The use of mobile health technology (mHealth) is another place where there is a 
tremendous amount of opportunity for expanded health education and awareness for family 
members. Currently, 96% of adults in the US. own a cell phone (Pew Research Center, 2019) 
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and mobile technology can be harnessed in many ways to offer support and education. Text-
messaging educational programs, for example, can be accessed on a cell phone allowing for the 
flexibility and anonymity that other family-focused prevention programming does not. 
An example of a text-based educational program for families is the Help & Hope by Text 
program provided by the Partnership to End Addiction (Partnership to End Addiction, n.d.-a). 
This free text-messaging intervention delivers messages to the family member’s cell phone on a 
daily basis. These messages provide both information (Help) and encouragement (Hope) to 
empower parents in support of their children who are misusing substances. Text messages are 
tailored to address unique family profiles. For example, gender-specific information is delivered 
to parents who are concerned about a daughter’s misuse of substances. Opioid-specific 
information is delivered to parents who are concerned about opioid misuse. The cost-involved in 
text messaging programs is relatively low when compared with traditional in-person prevention 
approaches. Once they have been developed, additional cost to maintain the programs is 
minimal. These digital health technologies have the potential to reach large numbers of family 
members who would otherwise not receive support and provide flexibility, anonymity and ease 
of use. 
Implications: Community 
At the prescriber level, policies that reduce opioid prescribing in situations when other 
pain treatment would be effective must be considered. Training doctors about responsible opioid 
prescribing and risk mitigation is key. Introducing more addiction training into medical school 
programs is important, as is ongoing continuing education for medical providers. An interesting 
initiative taken in Staten Island was conducted by New York City’s Department of Health and 
Mental Hygiene (DOHMH) (Kattan et al., 2016). In response to high opioid prescribing rates and 
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high overdose rates in Staten Island, DOHMH launched a public health detailing campaign. 
Public health detailing is modeled after pharmaceutical detailing and consists of individual health 
specialists meeting with health providers one-on-one to share health information. In this 
particular project, 866 health care providers in Staten Island received in-person visits from health 
educators over a two-month period in 2013. The educational campaign focused on judicious 
opioid prescribing and had three major recommendations for prescribers: (1) prescribing a 3-day 
supply of opioids for acute pain scenarios; (2) avoiding opioid prescribing for the long-term 
treatment of noncancer pain; and (3) replacing high-dose opioid prescriptions with lower 
dosages. When prescribing data from before and after the campaign were compared, the high-
dose prescribing rate was observed as decreasing more in Staten Island when compared with 
other boroughs during the same time period and knowledge about prescribing practices increased 
(Kattan et al., 2016). These kinds of direct-to-provider educational efforts are a way to provide 
continuing education to prescribers after they have left their training programs. 
In regards to stigma reduction, the two most common approaches are education and 
contact (Corrigan & Nieweglowski, 2018). The dissemination of evidence-based information 
about addiction is an important place to start. As was discussed above, individual and family-
focused prevention programs can educate both students, teachers and parents about substances 
and addiction. 
Increasing contact with others that are struggling (Corrigan & Nieweglowski, 2018) is 
another way to decrease stigma. As was observed in the study, stigma around addiction inhibited 
participants’ ability to get the support they needed from their families. One program that seeks to 
increase contact between families of those who are at risk or struggling is another intervention 
sponsored by The Partnership to End Addiction (Partnership to End Addiction, n.d.-b). The 
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Partnership has developed a nationwide peer-to-peer coaching program where a parent who has a 
child misusing substances is paired with a trained volunteer parent with lived experience. This 
Parent Coaching program allows parents to connect with other parents for education, validation 
and support. The intervention uses the Invitation to Change Approach (Wilkens & Foote, 2019) 
combining several evidence-based interventions including The Community Reinforcement 
Approach and Family Training (CRAFT), Motivational Interviewing (MI) and Acceptance and 
Commitment Therapy (ACT). An initial evaluation of this program showed that participants 
reported a reduction in their emotional distress and improved helping strategies after 
participation in five phone calls with a peer coach (Carpenter et al., 2020). 
Addressing boredom and lack of meaning are important areas of intervention at the 
community level as well. Finding meaningful activities in which youth can engage is important. 
Connecting youth to activities that are not only recreational but that also provide a sense of 
purpose and allow them to contribute to their communities in meaningful ways is something that 
communities must prioritize. These activities can involve social or environmental activism, 
volunteering to help those in need such as older adults, people with disabilities, or individuals 
with chronic illnesses. Creative pursuits such as art, music or drama can also provide 
opportunities for meaningful engagement. Being “bored” is more than just having a place to go 
bowling, although recreational opportunities are certainly important. Boredom can also signal the 
need to engage in the world in a way that feels meaningful and finding purpose. 
Limitations 
A major limitation of the study was the research sample’s lack of diversity in 
racial/ethnic representation. Despite a concerted effort on the part of the PI to recruit non-White 
participants, the sample was largely Caucasian. As a result, it was impossible to fully address the 
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research question involving the role of race or ethnicity in the experiences of research 
participants. Despite the lack of heterogeneity of the sample, some interesting findings did 
emerge from participants who identified as Italian-American about the role that Italian ethnic 
heritage played in terms of their own and others’ substance use trajectories. These participants 
pointed to intense stigma around those struggling with substances, thereby making it difficult for 
them to seek help from their parents, or for parents to go to their own communities for support. 
Another limitation was the lack of diversity reflecting sexual orientation. Only one participant 
identified as gay/lesbian and thus it was difficult to determine whether there were any themes 
common among gay/lesbian women in the sample. Future research should include a greater 
diversity of participants with regards to race, ethnicity and sexual orientation. 
Another study limitation was that there is no group of men with whom to directly 
compare these data. The analysis hypothesizes that certain findings are gender-sensitive but these 
hypotheses can’t be directly tested against a sample of men with similar experiences. A similar 
study conducted with young men would provide a comparison group that would allow for further 
development of the questions around the gendered components of POM. 
And finally, these findings may or may not generalize to other populations of young 
women in other time periods and in other locations. Because the sample was specifically 
designed to capture the lived experience of young women in the New York City borough of 
Staten Island, this work cannot even be necessarily compared with the experiences of young 
women in other New York City boroughs.. While this is a limitation, the purpose of a small, 
explorative qualitative study such as this is not necessarily to generalize findings to larger 
populations, but to explore a little-understood phenomenon in greater depth. In this case, a 
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deeper understanding of the lived experiences of these women allows for the discovery of new 
and potentially important information that is difficult to access via quantitative research.  
Conclusion 
In addition to the implications for practice and policy initiatives at the individual, 
interpersonal and community levels discussed above, this study highlights particular research 
needs as well. More research is required to further develop the initiation trajectory described in 
this work. In particular, more work is needed to understand the experiences of non-White 
women, Latinx women and women who identify as LGBTQ as these were subgroups that were 
not extensively represented in this sample. More research is needed in order to understand how 
opioids are used in conjunction with other psychoactive substances, particularly 
benzodiazepines. Similar qualitative research with men would also further the understanding of 
gendered-factors in prescription-opioid trajectories. 
 This qualitative study has explored the experiences of a group of young women and their 
POM initiation trajectories on Staten Island and has provided answers to a specific group of 
questions concerning these experiences. A grounded theory has emerged from the interviews and 
key themes were extracted which lead to a particular set of practice, policy and research 
recommendations. The suffering and pain associated with prescription opioid misuse is 
tremendous, and was shared by all of the women who participated in the study. In some cases, 
participants were in recovery and their stories were shared from a place of hope and 
accomplishment. Other women were still engaged in substance misuse when they were 
interviewed. They had been unable to move out of this behavior and continued to struggle with 
active addiction. I hope that this study helps to inform future interventions that will protect 
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young girls of today from the devastating experiences of POM and prevent them from the pain 






This work avoids the term addiction when at all possible. The word addiction has taken 
on multiple meanings in conventional usage and can refer to a wide range of problematic 
behaviors that include gambling, shopping, food and Internet use. Because it is used so often and 
has come to encompass so many varied meanings, this author prefers to avoid the term 
altogether. The word addiction also suggests a binary conceptualization of substance use—
someone is either addicted or not addicted. In contrast, this study conceptualizes substance use as 
a continuum of behavior from complete absence of use on one end of the spectrum to very 
problematic, chronic use on the other (Doweiko, 2012). Substance use that results in problematic 
outcomes will be referred to in this study as substance misuse or problematic use. 
Drugs and Substances 
The word drug is also problematic and is also avoided in this study to the extent possible. 
The word drug is associated with a moralistic attitude, a presumption of illegality, and an 
assumption of harm. In this work, the term substance is used when referring to any psychoactive 
agent that directly alters normal functioning of the central nervous system, i.e., an agent that 
changes mood, levels of perception or brain functioning (Inaba & Cohen, 2011). Examples of 
substances referred to in this study include alcohol, nicotine, caffeine, marijuana, cocaine, 
heroin, opium, oxycodone and hydrocodone. The word substance is generally a more neutral and 
less value-laden term than the word drug. In addition, substance includes psychoactive agents of 
both legal and illegal origin that are commonly used in the United States, such as nicotine and 
alcohol. The socially constructed distinctions between legal and illegal substances is frequently a 





This study is primarily concerned with prescription opioids (also known as painkillers, 
prescription opioids or opioid analgesics) which are part of the larger opioid family of 
substances. The term opioid refers to the entire group of narcotic analgesics comprised of (a) 
opiates, (b) semisynthetic opiates and (c) fully synthetic opioids. Opiates are natural derivatives 
of opium from the poppy plant and include substances such as morphine and codeine. 
Semisynthetic opioids are chemically modified opiates, such as hydrocodone (e.g., Vicodin), 
hydromorphone, oxycodone (e.g. OxyContin, Percocet), oxymorphone and heroin. Fully 
synthetic opioids are manufactured entirely from synthetic materials. Examples of these include 
fentanyl, methadone, and tramadol (Booth, 1999, p. 82). The prescription opioids considered in 
this study are found in all three groups of opiates, semisynthetic opiates and fully synthetic 
opioids. 
All opioids, regardless of route of administration, legal status or origin have 
similar effects on the human body. They all act by attaching to opioid receptors located 
in the brain, spinal cord, gastrointestinal tract and other organs (Inaba & Cohen, 2011). 
Medical practitioners today prescribe opioids for three primary purposes: to reduce pain, 
to control coughing, and to treat diarrhea. However, these opioids can also reduce 
anxiety and depression, induce euphoria, cause drowsiness, and blunt emotional pain. 
They also have other physiological effects including nausea, constipation and 
respiratory depression. Opioids are highly effective prescription opioids when used to treat acute 
and short-term pain conditions; research regarding their effectiveness in the 
treatment of long-term pain conditions is more controversial (Fields, 2007; Streltzer J, 2005). 
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A prescription opioid is distinguished from others in the opioid family only in that (1) it 
is intended for use under a medical professional’s supervision and (2) it originates as a legally 
manufactured and distributed substance. Prescription opioids and illicit opioids such as heroin 
share similar physiological effects. All opioid users experience the physiological experiences of 
tolerance, dependence and withdrawal, regardless of whether the opioid was derived licitly or 
illicitly. 
Opioid Abuse, Opioid Dependence and Opioid Use Disorders 
Up until recently, researchers investigating substance use issues frequently used the terms 
abuse and dependence when characterizing a diagnosable substance use disorder. These terms 
came from the version of the Diagnostic and Statistical Manual of Mental Disorders (American 
Psychiatric Association, 2000) published in the year 2000, commonly referred to as the DSM IV-
TR. In the DSM-IV-TR a diagnosis of opioid abuse required the presence of at least one of four 
criteria over a 12-month period. These criteria included consequences of use such as a failure to 
fulfill major role obligations, recurrent use in physically hazardous situations and continued use 
despite persistent social problems. The term opioid dependence referred to the presence of three 
out of seven criteria, different from those used to define opioid abuse. These criteria had to be 
present in a 12-month period and included consequences of habitual use such as tolerance, 
withdrawal, repeated attempts and failures to quit, and continued use despite knowledge of 
adverse consequences. 
The American Psychiatric Association’s (APA) newest version of the DSM was released 
in May 2013. The Diagnostic and Statistical Manual of Mental Disorders (American Psychiatric 
Association, 2013) has significantly changed the way substance use problems are conceptualized 
and diagnosed. In the new version, the APA has combined the DSM-IV-TR categories of abuse 
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and dependence into a single entity referred to as a substance use disorder. Under this new 
diagnostic system, an opioid use disorder is diagnosed if there is a “problematic pattern of opioid 
use leading to clinically significant impairment or distress…occurring within a 12-month period” 
(American Psychiatric Association, 2013). Substance use disorders are now located on a 
continuum of mild to severe based on the number of symptoms an individual endorses. 
Symptoms include the following:  
1. Opioids are often taken in larger amounts or over a longer period than was intended. 
2. There is a persistent desire or unsuccessful efforts to cut down or control opioid use. 
3. A great deal of time is spent in activities necessary to obtain the opioid, use the 
opioid, or recover from its effects. 
4. Craving, or a strong desire or urge to use opioids. 
5. Recurrent opioid use resulting in a failure to fulfill major role obligations at work, 
school, or home. 
6. Continued opioid use despite having persistent or recurrent social or interpersonal 
problems caused or exacerbated by the effects of opioids. 
7. Important social, occupational, or recreational activities are given up or reduced 
because of opioid use. 
8. Recurrent opioid use in situations in which it is physically hazardous. 
9. Continued opioid use despite knowledge of having a persistent or recurrent physical 
or psychological problem that is likely to have been caused or exacerbated by the 
substance. 
10. Tolerance, as defined by either of the following: 
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a. A need for markedly increased amounts of opioids to achieve intoxication or 
desired effect. 
b. A markedly diminished effect with continued use of the same amount of an 
opioid. 
11. Withdrawal, as manifested by either of the following: 
a. The characteristic opioid withdrawal syndrome (refer to Criteria A and B of the 
criteria set for opioid withdrawal, pp. 547–548). 
b. Opioids (or a closely related substance) are taken to relieve or avoid withdrawal 
symptoms. (American Psychiatric Association, 2013) 
Because the DSM-5 is relatively new in the field, much of the substance misuse literature 
continues to use both DSM-IV-TR and DSM-5 diagnostic categories, and the terms abuse, 
dependence, and disorder are all still used regularly. 
Prescription Opioid Misuse 
There are numerous terms used to describe situations in which prescription opioids are 
used in a manner other than through a medical professional’s prescription and supervision. 
Prescription opioid misuse is a term frequently found in the extant literature, as are the terms  
Nonmedical prescription opioid use or non-medical opioid analgesic use. The term prescription 
opioid misuse (POM) is used most often in this study and defined as “use without a prescription 
of the individual's own or simply for the experience or feeling the drugs caused” (Substance 
Abuse and Mental Health Services Administration, 2012b). Clearly, this definition encompasses 
a broad spectrum of substance use experiences, ranging from a single experimental event, to self-
treatment of a pain condition, to extensive problematic use. This study employs this definition as 
well, with the understanding that it might overestimate the extent of problematic use by 
126 
 
encompassing such a large range of possible substance use experiences. 
Tolerance 
When opioids are used for extended periods of time, tolerance can develop. Tolerance is 
the body’s attempt to protect itself from a psychoactive substance by altering brain and body 
chemistry, speeding up metabolism, desensitizing nerve cells and excreting the substance more 
rapidly (Inaba & Cohen, 2011). As the body acclimates to regular ingestion of a substance, the 
user must increase the amount used in order to achieve the same effects. Physical dependence 
occurs when the body has changed significantly due to continued use. Tolerance and physical 
dependence can extend to other opioids and is known as cross-tolerance or cross-dependence. If 
a user develops tolerance to and dependence on oxycodone, they will also have tolerance to and 
dependence on heroin. This scenario is observed in situations when someone misusing 
prescription opioids uses heroin as a substitute opioid to achieve similar effects, or when 
methadone is used as a replacement opioid in the treatment of opioid dependence. 
Withdrawal 
Once the body has become physiologically dependent on an opioid, withdrawal 
occurs if the opioid is no longer ingested. The body tries to return to normal too quickly 
and the individual experiences a rebound affect as a result (Inaba & Cohen, 2011). Opioid 
withdrawal symptoms include bone, joint and muscle pain, insomnia, anxiety, 
sweating, runny nose, stomach cramps, diarrhea, vomiting, fever, chills, goose flesh, 
and rapid pulse. Withdrawal is not life threatening but can be extremely uncomfortable and very 
painful. The fear of withdrawal can become a powerful motivator for continued use, even 
stronger than the desire to experience euphoria. The opioid user must maintain opioid use in 







Appendix B: Eligibility Screening Script 
 
 
Participant Code: ______________________________________________ 
THE CITY UNIVERSITY OF NEW YORK 
Hunter College  
School of Social Work  
 
ELIGIBILITY SCREENING SCRIPT 
 
Title of Research Study:  Nonmedical Prescription Opioid Use Among Young Women: A 
Qualitative Study 
 
Principal Investigator: Rachel Chernick, LCSW 
        Doctoral Candidate, CUNY Graduate Center--Social Welfare 
 
 
“Thank you for talking with me about this research project. In this study, we are trying 
understand how and why young women begin to use prescription opioids. I would like to ask you 
a few questions to determine whether you qualify to participate. Would you like to continue with 
the screening?” 
o If no: thank the person and hang-up. 
o If yes: continue with the screening. 
 
“Are you currently under the influence of drugs or alcohol?” 
o If yes: “Unfortunately, I cannot continue with the screening if you are under the 
influence. Can we set up another time to complete the screening when you are not under 
the influence?” 
o If no: continue with the screening. 
 
“The screening will take about ten minutes. I will ask you a few demographic questions and then 
a little bit about your history of prescription opioid use. You do not have to answer any questions 
you don’t want to answer or are uncomfortable answering, and you may stop at any time. Your 
participation in the screening is voluntary.” 
 
“The research team will make our best efforts to keep your answers to this screening 
confidential. No one except for the research team will have access to your answers. If you do not 
qualify for the study, your answers will be destroyed. If you do qualify for the study, your 
answers will be kept together with the rest of your research record. Would you like to continue 
with the screening?” 
o If no: thank the person and hang-up. 
o If yes: continue with the screening. 
 
Screening Criterion #1: Female 
“What is your gender? Male/Female/Transgender?” 
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o If male or transgender: thank the person and tell them they are not eligible to participate 
in the study. 
o If female: continue with the screening. 
 
Screening Criterion #2: Ages 18-34 (Inclusive) 
 “How old are you?” ________________________________ 
o If not 18-34: thank the person and tell them they are not eligible to participate in the 
study. 
o If yes 18-34: continue with the screening. 
 
Screening Criterion #3: History of Nonmedical Prescription Opioid Use 
“For the next few questions I’ll use the word “pills” to describe prescription opioids like 
OxyContin, Percocet or Roxicodone. I am not talking about other kinds of pills you might have 
used like benzos such as Xanax or Klonopin or stimulants like Ritalin or Adderall. I’m ONLY 
talking about pills in the opioid family.” 
 
“Have you ever used opioid pills for non-medical purposes? This means, you used pills (1) either 
without your own prescription, or (2) simply for the feeling or the experience that they caused” 
o If no: thank the person and tell them they are not eligible to participate in the study. 
o If yes: continue with the screening. 
 
Screening Criterion #4: History of Nonmedical Prescription Opioid Use Preceding Heroin 
Use 
“Have you ever used heroin?” 
o If no: move to Criterion #5 
o If yes: “Was the first time you used heroin before you started using pills? Or was the first 
time you used heroin after you started using pills?” 
o If heroin before pills: thank the person and hang-up. 
o If pills before heroin: move to Criterion #5 
 
Screening Criterion #5: Location of Nonmedical Prescription Initiation  
“In what city or town were you the very first time you used prescription opioids?” 
o If not New York City: thank the person and hang-up. 
o If in New York City: move to Criterion #6 
 
Screening Criterion #6: Meets at least four out of eleven criteria necessary for a DSM 5 
diagnosis of Opioid Use Disorder. 
 
“During the time you were using pills, did you experience any of the following over a one-year 
time period?” 
 Did you take more pills than you meant to or did you take pills over a longer period of 
time than you meant to? 
 Did you want to or try to cut down on your use? 
 Did you spend a lot of time trying to get pills, use pills or recover from using pills?  
 Did you ever have cravings to use pills? 
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 Did you continue to use even though you might have been having trouble keeping up 
with work, school or home responsibilities?  
 Did you continue to use even though you had problems with family or friends that were 
caused or made worse by opioid pills?  
 Did you have to give up social, work or recreational activities because of your use? 
 Did you continue to use in situations which might have been dangerous? 
 Did you continue to use even though you knew you might have been making a health or 
mental health problem worse by using? 
 Did you develop tolerance to pills, that is: 
o Did you have to use more and more pills to get the same effect? 
o Did you feel much less effect from using the same amount of pills as you had 
used previously? 
 Did you ever experience withdrawal from pill use? 
o Did you feel any of the following after 
o Did you ever take another opioid to relieve or avoid withdrawal symptoms? 
 
o If less than 4 criteria are met: Explain that the person is not eligible and thank them for 
their time. 
o If 4 or more criteria are met: Explain that the person is eligible to participate and set up a 
time for an in-person interview. 
 
“Do you have any questions about the screening or the research?  I am going to give you a 
couple of telephone numbers to call if you have any questions later. If you have questions about 
the research screening, you may call me at 718-541-1274. If you have questions about your 
rights as a research participant, or if you wish to voice any problems or concerns to someone 
other than the researchers, please call CUNY Research Compliance Administrator at 646-664-
8918.” 
 






Appendix C: Interview Guide 
Participant Code: ______________________________________ 
THE CITY UNIVERSITY OF NEW YORK 




1. Demographics: These are some questions about your gender, age, education, etc. 
o What is your age? 
 ______ 
o How do you describe your race? 
 ______ Black/African-American 
 ______ White/Caucasian 
 ______ Hispanic/Latino 
 ______ Asian/Pacific Islander 
 ______ Native American/ 
 ______ Multi-racial 
 ______ Other 
o Do you consider yourself straight, bisexual, gay, or something else? 
 ______ Straight/Heterosexual 
 ______ Gay/Lesbian/Homosexual 
 ______ Bisexual 
 ______ Undecided 
o What is the zip code of your primary residence? 
  ____________________ 






o What is the highest level of education you have completed? 
 ____________________ 
o What is your current relationship status? 
 Single 
 Monogamous Partner 
 Partner (open or non-monogamous) 
 Other 




o What is the total income for your household this past year? 
 ____________________ 
o What is your mother's occupation? 
 ____________________ 
o What is your mothers' level of education? 
 ____________________ 
o What is your father's occupation? 
 ____________________ 
o What is your father's level of education? 
 ____________________ 
 
2. Substance Use History: This next set of questions will cover your history of using 
legal drugs, illegal drugs, and prescription drugs. 
























Alcohol         
Marijuana         
K2         
Ecstasy         
Mushrooms/LSD         
Heroin         
Crack         
Cocaine         
PCP         
Speed/Crystal meth         









     
Hydromorphone 
(Dilaudid®) 
     
Oxymorphone 
(Opana®)   
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Fentanyl      
Codeine (Tylenol with 
codeine®) 
     
Tramadol (Ultram®, 
Ultracet®) 
     








     
 Adderall®, Ritalin®, 
Concerta® 
     
 
3. Initiation Experience: 
o Can you tell me about your first experience using prescription painkillers? 
(Prompts: Where were you? How were you using? Who else was there? How 
were you feeling about using? What did you do after you used? 
o How would you describe this experience? (Prompts: How did you feel while you 
were high/after you were high? Did you talk about getting high with anyone 
else?) 
o How would you describe how you viewed pills before and after you used them 
that first time? 
o Could you describe the events that led up to this first time using? (Prompts: What 
was going on in your life then? What kinds of things do you think contributed to 
this first use?) 
o How would you describe the person you were then? 
4. Subsequent Use 
o Can you tell me about the next time you used? (Prompts: How was this 
experience different from the first time?) 
o Can you tell me a little bit about how your use changed over time? 
o When did you first realize that your use had become problematic? 
5. Peer Influence 
o  How would you describe the group you were hanging out with when you started 
using? (Prompts: Were you more of a follower in your crowd? Or a leader? Was 
this group mostly guys or girls?) 
o What kinds of things did you learn about drugs from your friends? 
o What kinds of drugs/alcohol were your friends using? (Prompts: When/Where 




o Did you ever use with your friends? (Prompts: What kind of drugs were you 
using?) 
o Were there differences in how guys and girls used drugs in your group? (Prompts: 
Different drugs? Different methods?) 
o Were there differences in how guys and girls talked about drugs and drug use? 
6. Family Influence 
o Can you describe the family you grew up with? (Prompts: Family 
composition/Dynamics? Relationships with parents/siblings? Parent's discipline 
style? Were your parents around a lot when you were a kid? 
o How would you describe your family's class background? 
o How would you describe your family's ethnic/racial background? 
o Does anyone in your family use drugs or alcohol? (including prescription drugs) 
o Does anyone in your family have a problem with drugs or alcohol? (including 
prescription drugs) 
o Have you ever used drugs or alcohol with family members? 
o Do people in your family know that you used painkillers? (Prompts: How do they 
feel about it?) 
7. Intimate Partner Influence 
o Were you involved with any romantic or sexual partners around the time you 
started using? 
o Can you tell me a little bit about this/these relationship/s? 
o How did this/these affect your use? 
o Did you use with your partner/s? What was that like? 
8. Prevention 
o What kind of formal drug education do you have in school? (Prompts: What was 
that like? Did they talk about prescription drugs specifically?} 
o How did it affect how you felt or thought about using drugs or alcohol? 
o Was there any other place (besides from friends) where you learned about drugs? 
(Doctor? Internet? Counselor/therapist?) 
9. Treatment/Harm Reduction 
o Have you participated in any drug treatment or harm reduction program since you 
began using pills? 
o What was this experience like for you? 
o What was helpful about this experience? 
o What was not helpful? 
o Did this treatment change the way you think about your drug use? 
10. Reflection 




o How do you understand your opioid use and why this become problematic for 
you? 
o How do you understand why the particular treatment that you received worked for 
you? 
o After having had this experience, how would you talk to a young woman who was 
thinking about using pills for the first time? 
o Is there something else you think I should know about to understand your 
experience better? 
o Is there something you would like to ask me? 
That’s the end of the interview. Thank you so much for talking with me today, I really 




Appendix D: Informed Consent 
THE CITY UNIVERSITY OF NEW YORK 
Hunter College 
School of Social Work 
 
CONSENT TO PARTICIPATE IN A RESEARCH STUDY 
 
Title of Research Study: Initiation of Nonmedical Prescription Opioid Use Among Young 
Women: A Qualitative Study 
 
Principal Investigator: Rachel Chernick, LCSW 
        Doctoral Candidate, CUNY Graduate Center--Social Welfare 
 
Faculty Advisor:  Alexis Kuerbis, LCSW, PhD  
      Associate Professor 
 
 
Are you currently under the influence of drugs or alcohol? 
 
o If Yes: Unfortunately, I cannot continue with the interview if you are under the influence. 
Can we set up another time to complete the screening when you are not under the 
influence?” 
o If No: continue with the consent process 
 
Study Description: You are being asked to participate in a research study because you are a 
young woman between the ages of 18 and 34 who began using prescription opioids nonmedically 
in New York City.  The purpose of this research study is to understand how and why young 
women begin and continue to use prescription opioids. 
 
Procedures:   
 
If you volunteer to participate in this research study, you will be asked to participate in a face-to-
face interview at Hunter College, School of Social Work at 2180 Third Avenue in Manhattan, 
NYC. The interview will take between one and two hours to complete. As part of the interview, 
you will be asked a series of questions including questions about yourself, your family and your 
social networks. There will also be questions about your history of using prescription opioid 
pills. We will NOT ask for any specific details about people involved in drug distribution or 




To ensure the accuracy of our findings, the interview will be audio recorded for later 
transcription and review by the research team. You can still participate in this study if you do not 
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consent to audio recording. You will be permitted to review, edit and/or erase the recording at 




Your participation in this research study is expected to last between one and two hours. 
 
Potential Risks or Discomforts:  
 
You may become upset or uncomfortable during the interview. If you would like, you may take a 
break and return to the interview at any time.  You may refuse to answer any questions without 
penalty and you may stop the interview at any time. A referral sheet for counseling services is 
available to you upon request. 
 
Potential Benefits:  
 
You will not directly benefit from your participation in this research study. The information that 




You will be notified about any new information regarding this study that may affect your 




You are not required to provide your name or any identifying details to participate in this study. 
All of your responses will be kept confidential. However, you should be aware that if you 
provide information during the interview of any clear and present danger to yourself or others, 
such as serious thoughts of suicide, current or future child abuse, intended assault or serious 
crimes, such information can be released without your consent to the appropriate agency. We 
will NOT be asking you direct questions about any of these things during the interview. 
 
Only the researchers involved in the study and those responsible for research oversight will have 
access to the information you provide. The interview will be audio-recorded and stored on a 
password-protected hard drive secured in a locked cabinet. Your responses will only be 
identified by a numerical code number that will be assigned to you at the beginning of the 
interview. Audio recordings will be transcribed by a transcription service that will not have 
access to any identifying information about you. Audio recordings will be transcribed by a 
transcription service that will not have access to any identifying information about you. Your 
audio file and corresponding written transcription will be labeled using your assigned numerical 
code number. 
 
We will make our best efforts to maintain confidentiality of any information that is collected 
during this research study and that can identify you. We will disclose this information only with 




Participants’ Rights:  
 
Your participation in this research study is entirely voluntary. If you decide not to participate, 
there will be no penalty to you, and you will not lose any benefits to which you are otherwise 
entitled. You can decide to withdraw your consent and stop participating in the research at any 
time, without any penalty. 
 
Payment for Participation:  
 
You will receive a $25 gift card for your time and a MetroCard in the amount of $5.50 to 
compensate you for travel expenses. 
 
Questions, Comments or Concerns:  
If you have any questions, comments or concerns about the research, you can talk to the 
following researcher: Rachel Chernick, 718-541-1274. 
 
If you have questions about your rights as a research participant, or you have comments or 
concerns that you would like to discuss with someone other than the researcher, please call the 
CUNY Research Compliance Administrator at 646-664-8918 or email HRPP@cuny.edu. 
Alternately, you can write to: 
 
CUNY Office of the Vice Chancellor for Research 
Attn: Research Compliance Administrator 
205 East 42nd Street 
New York, NY 10017 
 
Do you have any other questions at this time? 
 














Appendix E: Referrals 
 
NYC WELL 
1-888-NYC-WELL or text “WELL” to 65173 
This number connects you to free, confidential mental health support. Speak to a counselor via 
phone, text or chat and get access to mental health and substance misuse services in more than 
200 languages. 
 
311 in NYC 
Call 311 for all kinds of information and referrals to mental health, health and addiction services. 
 




New York State Authorized Syringe Exchange Programs 
https://www.health.ny.gov/diseases/aids/consumers/prevention/needles_syringes/docs/sep_hours
_sites.pdf or call 311 
 
New York State Office of Alcoholism and Substance Abuse Services 
https://www.oasas.ny.gov/ 
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All of a sudden like you get this wave of warmth, you get this like, “Ahhhh,” 
like, you know, like everything’s right with the world all of sudden. (Chloe)  
I have never used opioids in a non-medical way, yet I identify strongly with the women 
in this study who have and continue to do so. I understand the intense struggle and deep pain that 
come with being human. I have lost loved ones and cried uncontrollably at their funerals. I have 
felt extreme shyness and awkwardness and been grateful for substances that allow me to feel 
comfortable socializing with others. I have felt the curiosity associated with trying a substance 
that my peers have tried. I have made poor decisions out of a desire to feel attractive or loved. I 
have felt the overwhelming stress and exhaustion associated with caring for a young child and 
trying to work and take care of a family at the same time. I understand the intense desire to feel 
like “everything’s right with the world”. The appeal of taking a pill that can instantaneously 
erase pain, sadness, grief, anxiety and depression is tremendously powerful.  
Over the many years that I have studied and researched addiction, the refrain that 
continues to echo in my mind is “there, but for the grace of God, go I.” It is only by the luck of a 
particular set of genetics and environmental factors that I was the interviewer and not the 
interviewee in this study. With a different role of the dice, the situation could easily have been 
reversed. I will never forget that as I continue to practice and research in this field.  
 
